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Evidence from our laboratories indicates that triterpene constituents of Syzygium cordatum 
(Hochst.) [Myrtaceae] crude leaf extracts can be used to treat diabetes mellitus. For the plant 
derived triterpenes to have further potential in diabetes management, they should, however, 
additionally alleviate or prevent some of the complications of diabetes mellitus such as 
impaired kidney function and cardiovascular disorders. Accordingly, this study was designed 
to isolate the triterpene, oleanolic acid (OA) from S. cordatum leaves and evaluate its effects 
on blood glucose, renal function and blood pressure in streptozotocin (STZ)-induced diabetic 
rats. OA was studied because it is the major constituent of many African plant species used 
in traditional medicine. 
Materials and Methods 
S. cordatum crude leaf ethyl acetate solubles (EAS) were obtained after defatting the leaves 
with hexane followed by dichloromethane before maceration with ethyl acetate. Preliminary 
experiments indicated that EAS contained triterpenes with hypoglycaemic properties. Solvent 
extraction and fractionation of EAS yielded mixtures of oleanolic acid/ursolic acid (OA/UA) 
and methyl maslinate/methyl corosolate. Recrystallisation of the OA/UA mixture using 
ethanol yielded OA, the structure of which was confirmed by NMR spectroscopy ('H & 13C). 
Oral glucose tolerance test (OGTT) responses to various doses of OA (40, 80 and 120 mg/kg) 
were monitored in separate groups of non-diabetic and STZ-induced diabetic rats given a 
glucose load (0.86 g/kg, p.o.) after an 18-h fast. Rats treated with deionized water (3 ml/kg 
p.o.), or standard drugs, (insulin, 200 Hg/kg, s.c; metformin, 500 mg/kg, p.o. and 
glibenclamide, 500 f̂ g/kg, p.o.) acted as untreated and treated positive controls, respectively. 
To investigate the possible interaction between OA and standard drugs in lowering blood 
glucose, OGTT responses were studied in separate groups of animals simultaneously treated 
xvi 
with OA at either 40 or 80 mg/kg and insulin (100 or 200 ug/kg, s.c), metformin, (250 or 
500 mg/kg, p.o.) or glibenclamide (250 or 500 mg/kg, p.o.). Blood glucose was monitored at 
15-min intervals for the first hour, and hourly thereafter for 3 h. Plasma insulin 
concentrations were measured in separate parallel groups of rats prepared as for OGTT 
studies to examine whether there was an association between OA treatment and pancreatic 
insulin secretion. Acute effects of OA on kidney function and mean arterial blood pressure 
(MAP) were investigated in anaesthetized rats challenged with hypotonic saline after a 3'/2-h 
equilibration for 4 h consisting of 1 h control, 1XA h treatment and 1 Vi h recovery periods. OA 
was added to the infusate during the treatment period. Short-term effects of OA were studied 
in individually-caged rats treated twice daily with OA (80 mg/kg, p.o.) for 5 weeks. 
Results 
OA decreased blood glucose concentrations of both non-diabetic and diabetic rats, as did 
some standard drugs except glibenclamide which did not exhibit any effects in STZ-induced 
diabetic animals. The blood glucose lowering effects were most potent in STZ-induced rats 
treated with combined OA and insulin by comparison with all other treatments. Short-term 
treatment of non-diabetic and STZ-induced diabetic rats with OA alone for 5 weeks 
decreased blood glucose concentrations, but the reduction in non-diabetic rats was to values 
that did not achieve statistical significance. Except for non-diabetic rats treated with insulin 
alone or in combination with OA, plasma insulin concentrations were not altered by 
treatment in non-diabetic and STZ-induced diabetic animals. Hepatic glycogen 
concentrations of non-diabetic and STZ-induced diabetic rats were significantly increased by 
all treatments at the end of 5 weeks. 
Acute intravenous infusion of OA in anaesthetized rats significantly increased Na+ excretion 
outputs of non-diabetic and STZ-induced diabetic rats without affecting urine flow, K+ or CI" 
excretion rates. Similarly, daily OA treatment (80 mg/kg, p.o.) significantly increased Na+ 
excretion rates of non-diabetic and STZ-induced diabetic rats throughout the 5 week 
experimental period without affecting urine flow, K+ or CI" excretion rates. By comparison 
with respective control animals, Short-term administrations of OA significantly (p<0.05) 
xvii 
increased GFR of non-diabetic (2.88±0.14 vs 3.71±0.30 ml/min) and STZ-diabetic rats 
(1.81± 0.32 vs 3.07±0.16 ml/min, n=6 in all groups) with concomitant reduction of plasma 
creatinine concentrations. Acute and Short-term administrations of OA non-diabetic and STZ-
induced diabetic rats reduced mean arterial blood pressure by comparison with respective 
control animals. 
Discussion 
The results suggest that S. cordatum leaf derived OA not only has the potential to lower 
blood glucose in diabetes, but also has beneficial effects on kidney function and blood 
pressure. We suggest that the hypoglycaemic effects of OA mimic those of metformin as 
evidenced by the fact that neither of these treatments altered plasma insulin concentration of 
non-diabetic rats. OA-evoked increases in urinary Na+ outputs of STZ-diabetic rats and 
elevation of GFR suggest up-regulation of renal function by the triterpene. The findings are 
of considerable importance because they suggest the hypoglycaemic, renal and hypotensive 
effects of OA in the management of diabetes mellitus. 
Conclusion 
The results demonstrated that the oleanolic acid extracted from S. cordatum leaf has blood 
glucose-lowering effects comparable to standard anti-diabetic drugs in STZ-induced diabetic 
rats. Furthermore, OA augmented the hypoglycaemic effects of insulin in STZ-induced 
diabetic rats. These findings suggest that OA may have beneficial effects on some of the 
processes that are associated with renal derangement in STZ-induced diabetic rats. The 
results introduce the first in vivo evidence that OA ameliorates kidney function in STZ-
induced diabetic rats. 
Keywords: Renal function; diabetes mellitus; triterpenoids; oleanolic acid, hypoglycaemia 
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CHAPTER 1 
1.0. INTRODUCTION/ LITERATURE REVIEW 
1.1. Background 
Diabetes mellitus is characterized by hyperglycaemia because glucose transport across the 
cells is impaired. The sustained hyperglycaemia leads to compromised kidney function and 
the development of microvascular and macrovascular complications through different 
mechanisms. Hence the goal in diabetes management is not only to maintain optimal blood 
glucose control, but also to avert these adverse outcomes. Current conventional diabetes 
therapy using blood glucose-lowering medications such as insulin or oral hypoglycaemic 
agents has limitations. For instance insulin therapy does not achieve glycaemic control in 
patients with insulin resistance, and oral hypoglycaemic agents may lose their efficacy after 
prolonged use. Alternative methods of lowering blood glucose are, therefore, needed. Herbal 
medicines have been used for many years by different cultures around the world, both for the 
prevention and management of diabetes (Kim, Kang, Park, Jung, Choi and Ku, 2007b). 
Previously the crude leaf extract of Syzygium cordatum (Hochst.) [Myrtaceae] has been 
shown to reduce blood glucose levels in streptozotocin (STZ)-induced diabetic rats perhaps 
due to its triterpene constituents. The study described in this dissertation was designed to 
isolate and investigate the blood glucose lowering and renal function effects of one of S. 
cordatum leaf derived triterpene constituents, oleanolic acid (3|3-hydroxy-olea-12-en-28-oic 
acid, OA) in STZ-induced diabetic rats. The effects of OA were investigated because it is the 
main triterpene that has been isolated from many medicinal plants, such as Momordica 
charantia (Linnaeus) [Curcubitaceae] (Kumar, Shetty and Salimath, 2008), Olea europaea 
(Linnaeus) [Oleaceae] (Chen, Liu, Zhang, Wu, Hua, Wu and Sun, 2006). The effects of OA 
on kidney function were also investigated to establish whether OA has beneficial effects on 
renal function in diabetes mellitus management. 
1 
1.2. Diabetes mellitus 
Diabetes mellitus is a chronic metabolic disorder due to acquired or inherited causes leading 
to absolute or relative deficiency of insulin or due to insulin resistance (Evcimen and King, 
2007). Diabetes can be classified into three main types: type 1, type 2 and gestational 
diabetes. Type 1 is due to autoimmune destructive lesions of P-cells of the pancreas leading 
to an absolute lack of insulin secretion. In type 2 which accounts for 90-95% of diabetic 
patients, there is a combination of decreased insulin secretion and insulin sensitivity (The 
Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus, 
2002; Jung, Park, Lee, Kang, Kang and Kim, 2006; World Health Organisation (WHO), 
2006). The third type, gestational diabetes is defined as the first onset of diabetes mellitus in 
women during pregnancy precipitated by an excess production of glucocorticoids (American 
Diabetes Association, 2004). 
According to WHO (2006), 180 million people have diabetes worldwide. Estimates are that 
by 2030 the number will more than double to about 366 million, making it an epidemic 
(Stovring, Andersen, Beck-Nielsen, Green and Vach, 2007). Chronic hyperglycaemia due to 
carbohydrate, lipid and protein metabolism disorders in diabetes mellitus leads to the 
development of macrovascular and microvascular complications (Rahimi, Nikfar, Larijani, 
Abdollahi, 2005). The hyperglycaemia occurs from alterations in the glucose homeostatic 
systems, resulting from impaired glucose transport across cells. The various ways through 
which glucose is transported are briefly described below. 
1.2.1. Glucose transport 
Glucose is transported across cell membranes through two main carrier proteins, sodium-
glucose co-transporters (SGLT's) and glucose transporters (GLUT). The two main isoforms 
of SGLT, SGLT-1 and SGLT-2 are mostly expressed in the intestine and kidney, respectively 
(Barnard and Youngren, 1992; Kakuda and MacLeod, 1994; Bouche, Serdy, Kahn and 
Goldfine, 2004). They utilize the electrochemical sodium gradient to transport glucose 
against a concentration gradient. Inhibition of glucose uptake by the SGLT's using phlorizin 
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is one of the strategies used in glycaemic control (Panayotova-Heiermann, Loo, Kong, Lever 
and Wright, 1996; Link and Sorensen, 2000). On the other hand, GLUT transporters are a 
family of 13 hexose transporters that passively transport monosaccharides, including glucose, 
down a concentration gradient. According to Bouche, Serdy, Kahn and Goldfine, (2004), 
these can be classified as high affinity (GLUT-1, 3, 4, 6, 8, 10 and 12) and low affinity 
(GLUT-2). GLUT-2 is expressed in pancreatic P-cells, and tissues with high glucose fluxes 
like intestine, liver and kidney. GLUT-1 is expressed mostly in erythrocytes, kidney, colon 
and cells of blood-tissue barriers like the blood brain barrier and at low levels in liver, 
adipose tissues and muscles (Bouche, Serdy, Kahn and Goldfine, 2004; Wiernsperger, 2005). 
GLUT-1 and GLUT-3 are the primary GLUT transporters in foetal and neuronal tissues, 
respectively (Bouche, Serdy, Kahn and Goldfine, 2004). GLUT-4 mediates insulin-
stimulated glucose uptake by skeletal muscles, heart, and white and brown adipose tissues. 
Insulin and exercise stimulate translocation of the GLUT-4 to the cell membrane from an 
intracellular pool (Barnard and Youngren, 1992; Bouche, Serdy, Kahn and Goldfine, 2004; 
Wiernsperger, 2005). In contrast, the GLUT-1 is expressed on the cell membrane in the 
absence of insulin. The activity of the GLUT transporters can, therefore, be insulin or non-
insulin mediated, with GLUT-1 contributing to about 75% of the glucose transport. In type 2 
diabetes mellitus, there are defects in GLUT-4 translocation due to insulin resistance and 
GLUT-1 is over-expressed (Miura, Itoh, Kaneko, Ueda, Ishida, Fukushima, Matsuyama and 
Seino, 2004; Wiernsperger, 2005). The high glucose influx in diabetes mellitus mediated via 
GLUT-1 transporters increases intracellular glucose metabolism leading to the development 
of complications. 
1.3. Aetiology of diabetic complications 
The metabolic pathways involved in the aetiology of diabetic complications are discussed in 
the following sections. 
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1.3.1. Polyol pathway 
Aldose reductase, the first enzyme in the polyol pathway, catalyzes the nicotinamide adenine 
dinucleotide phosphate (NADPH)-dependent reduction of glucose to sorbitol which is 
oxidized to fructose by sorbitol dehydrogenase, an enzyme that uses NAD+ as a cofactor 
(Brownlee, 2001; Sheetz and King, 2002; Lorenzi, 2007). This pathway is activated in 
diabetes mellitus in non-insulin sensitive tissues including the lense, peripheral nerve and the 
glomerulus (Brownlee, 2001; Sheetz and King, 2002; Lorenzi, 2007). Studies suggest that 
sorbitol evokes osmotic vascular damage and cataracts in the eyes (Sheetz and King, 2002; 
Lorenzi, 2007). The involvement of sorbitol in osmotic vascular damage, however, is often 
difficult to rationalize (Brownlee, 2001; Sheetz and King, 2002). Additionally, diabetic 
complications arise from advanced glycosylating agents formed by the breakdown of 
fructose (Brownlee, 2001; Lorenzi, 2007). Development of diabetic complications also 
involves decreasing the activity of enzymes that use NADPH/NADH as a cofactor. The 
enzymes include glutathione reductase which would cause redox imbalances due to depletion 
of reduced glutathione levels (Brownlee, 2001; Sheetz and King, 2002; Vincent, Russel, Low 
and Feldman, 2004; Lorenzi, 2007). Endothelial generation of nitric oxide is also impaired by 
the decreased NADPH levels. In addition there is inhibition of glyceraldehyde-3-phosphate 
dehydrogenase (GADPH), leading to an increase in triose phosphate. This increases the 
formation of methylglyoxal, a precursor of advanced glycation end products (AGE's) and 
diacylglycerol (DAG), which activates protein kinase C (PKC) (Brownlee, 2001). Despite the 
osmotic damage, studies suggest that oxidative stress is the main cause of cellular damage by 
the polyol pathway (Lorenzi, 2007). 
Inhibition of aldose reductase by various synthetic drugs such as zenarestat and sorbinil and 
anti-diabetic plants has been effective in preventing and alleviating complications associated 
with diabetes mellitus (Brownlee, 2001; Lorenzi, 2007). Plant extracts of Stelechocarpus 
cauliflorous [Annonaceae] and its glycoside derivatives engeletin and astilbin have been 
reported to inhibit aldose reductase (Wirasathiena, Pengsuparpa, Suttisria, Uedab, Moriyasub 
and Kawanishib, 2007). Reno-protective effects were seen with berberine, one of the main 
constituents of Coptis chinensis (Franch) [Ranunculaceae] and Phellodendron amurense 
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(Ruprecht) [Rutaceae], and this was associated with a concomitant inhibition of oxidative 
stress (Wei-ha, Zi-qing, Hong, Fu-tian, He-qing, Xue-juan, Yan-hui, Shao-rui, Fen-fen, Wen-
ge, Feng-ying and Pei-qing, 2008). Other isolated bioactive compounds from plants that 
inhibit aldose reductase activity include quercetin, silymarin, fiavonoids and puerarin 
(Adaramoye and Adeyemi, 2005; Li, Dai, Yu, Li, Wu, Luan, Meng, Zhang and Deng, 2007). 
Reduced activity of aldose reductase prevents production of sorbitol and its downstream 
stimulation of the formation of AGE's and PKC pathways which are described in the next 
sections. 
1.3.2. Advanced glycosylation end products (AGE's) 
The formation and accumulation AGE's from dicarbonyl compounds is accelerated in 
diabetes. Major sources of the carbonyl group in the glycation reaction include glucose and 
carbonyl compounds, such as glyceraldehyde (Sakurai, Yonekura, Yamamoto, Watanabe, 
Tanaka, Li, Rahman, Myint, Kim and Yamamoto, 2003). The dicarbonyl compounds react 
irreversibly with amino groups of intracellular and extracellular proteins in the Maillard 
reaction to form AGE's (Brownlee, 2001; Sheetz and King, 2002; Sakurai et al., 2003; 
Yonekura, Yamamoto, Sakurai, Watanabe, and Yamamoto, 2005; Thallas-Bonke, Thorpe, 
Coughlan, Fukami, Yap, Sourris, Penfold, Bach, Cooper and Forbes 2008). The structure and 
function of proteins, such as serum albumin, lens crystallin, intracellular proteins and 
collagen in the extra cellular matrix is altered by advanced glycation end products (AGE's) 
(Brownlee, 2001; Sheetz and King, 2002; Sakurai et al, 2003; DeGroot, 2004). Altered cell 
function by AGE's occurs through the receptor for AGE's (RAGE) on endothelial cells, 
mesangial cells and macrophages (Brownlee, 2001; Sheetz and King, 2002; DeGroot, 2004; 
Yonekura, Yamamoto, Sakurai, Watanabe, and Yamamoto, 2005). Activation of the receptor 
has been reported to induce production of reactive oxygen species through activation of the 
nuclear transcription factor-KP (Brownlee, 2001; Yonekura, Yamamoto, Sakurai, Watanabe, 
and Yamamoto, 2005). This occurs via a cascade of cellular signalling events, such as 
activation of mitogen-activated protein kinase (MAPK) or PKC, which can lead to cellular 
dysfunction (Sheetz and King, 2002). Additionally AGE's have been shown to reduce matrix 
protein flexibility through modification of extra-cellular matrix proteins leading to an 
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abnormal interaction with other matrix components and the receptors for matrix components 
on cells (Brownlee, 2001; Hartog, Voors, Bakker, Smit and van Veldhuisen, 2007). The 
activation of these events leads to development of diabetic complications like retinopathy, 
nephropathy and atherosclerosis. There are various strategies that can be used to prevent the 
effects of AGE's accumulation. These may involve glycaemic control which prevents the 
glucose-dependent first step in the Maillard reaction or use of antioxidants like flavonoid that 
inhibit the final Maillard step catalyzed by oxidative stress. In diabetic atherogenesis, 
blocking or genetically deleting the receptor for advanced glycation end product (RAGE) in 
experimental animals reverses atherosclerosis (Ihara, Egashira, Nakano, Ohtani, Kubo, Koga, 
Iwai, Horiuchi, Gang, Yamagishi and Sunagawa, 2007). Amino guanidine and pyridoxamine, 
AGE's formation inhibitors, have reno-protective effects in diabetic animals (Lassila, Seah, 
Allen, Thallas, Thomas, Candido, Burns, Forbes, Calkin, Cooper and Jandeleit-Dahm, 2004; 
Hartog, Voors, Bakker, Smit and van Veldhuisen, 2007). Furthermore, inhibition of AGE's 
effects can be achieved through breaking of the AGE's cross links by drugs such as 
alagebrium and also by inhibiting AGE signal transduction (incadronate disodium and 
cerivastatin) (Hartog, Voors, Bakker, Smit and van Veldhuisen, 2007). Additionally various 
medicinal plants and their derived compounds have been shown to prevent the complications 
in diabetes mellitus through inhibition of the AGE's or RAGE formation. The extracts of 
Panax quinquefolium (Linnaeus) [Araliaceae] and plant-derived bioactive compounds 
resveratrol, a phytoestrogen from Vitis vinifera (Linnaeus) [Vitaceae]; curcumin from 
Curcuma longa (Linnaeus) [Zingiberaceae] and glycosides from Stelechocarpus cauliflorus 
(R.E. Fr) [Annonaceae] have been reported to inhibit formation of AGE's or RAGE (Sheetz 
and King, 2002 Rahbar and Figarola, 2003; Kim, Kang, Yamabe, Nagai, Yokozawa, 2007a; 
Wirasathiena et ah, 2007). 
1.3.3. Protein kinase C 
PKC is a family of at least twelve enzyme isoforms which are involved in the development of 
diabetic complications (Brownlee, 2001; Sheetz and King, 2002; Evcimen and King, 2007). 
Nine of the PKC isoforms (including PKC-a, pi, pil, y, 8, 8 and £,) are activated by the 
second messenger diacyl-glycerol (DAG), a critical signalling molecule that regulates many 
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vascular functions such as permeability, growth factor signalling, vasodilator release and 
endothelial activation (Brownlee, 2001; Aiello, 2002; Sheetz and King, 2002; Khan and 
Chakrabarti, 2007). DAG levels are increased both in vascular tissues, including those of the 
aorta, heart and renal glomeruli and also in non vascular tissues such as liver and skeletal 
muscles in diabetes mellitus (Brownlee, 2001; Sheetz and King, 2002; Evcimen and King, 
2007). Multiple pathways have been shown to increase DAG levels in the diabetic state and 
one such is hydrolysis of phosphatidylcholine by phospholipase C (Brownlee, 2001; Sheetz 
and King, 2002; Evcimen and King, 2007). The generation of the reactive oxygen species, 
like hydrogen peroxide in the polyol pathway also activates PKC (Brownlee, 2001; Aiello, 
2002; Sheetz and King, 2002; Vincent, Russel, Low and Feldman, 2004; Evcimen and King, 
2007). 
The activation of PKC is associated with changes in blood flow, basement membrane 
thickening, extra cellular matrix expansion, vascular permeability, angiogenesis, cell growth 
and enzymatic activity alterations (Evcimen and King, 2002). In early diabetes, activation of 
PKC has been implicated to impair retinal and renal blood flow possibly by increasing 
endothelin-1 levels (Brownlee, 2001). The effects of PKC activation on nitric oxide are 
unclear though there is evidence of reduced production of nitric oxide (Brownlee, 2001; 
Evcimen and King, 2007). PKC activation also increases directly the permeability of 
macromolecules across endothelial or epithelial barriers by phosphorylating cytoskeletal 
proteins or indirectly by regulating expression of various growth factors such as vascular 
endothelial growth factor (VEGF) (Brownlee, 2001; Aiello, 2002; Evcimen and King, 2007). 
Most of the manifestations due to PKC activation in diabetes mellitus are reversed with the 
use of PKC inhibitors (Evcimen and King, 2007). One such is ruboxistaurin, a PKC-P 
inhibitor which has been shown to reverse haemodynamic changes in retinopathy, 
nephropathy and neuropathy (Sheetz and King, 2002; Evcimen and King, 2007). 
1.3.4. The hexosamine pathway 
The hexosamine biosynthesis pathway (HBP) is a relatively minor branch of glycolysis. It 
involves conversion of fructose-6-phosphate to glucosamine-6-phosphate by the enzyme 
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glutamine: fructose-6-phosphate amidotransferase (GFAT). The major end-product is uridine 
diphosphate-iV-acetylglucosamine (UDP-GlcNAc) which along with other amino-sugars 
generated by hexosamine biosynthetic pathway (HBP) provides essential building blocks for 
glycosyl side chains, of proteins and lipids (Buse, 2006). Shunting of excess intracellular 
glucose into the HBP may account for several manifestations of diabetic renal and vascular 
complications (Buse, 2006). This implies that under hyperglycaemic conditions there are 
increased amounts of fructose-6-phosphate diverted from glycolysis that provide substrates 
for reactions which require UDP-vV-acetylglucosamine, such as proteoglycan synthesis and 
the formation of O-linked glycoproteins (Brownlee, 2001). The altered protein function due 
to O-linked GlcNAcylation results in diminished expression of sarcoplasmic reticulum Ca2+-
ATPase in cardiomyocytes and induction of TGF-P and plasminogen activator inhibitor-1 in 
vascular smooth muscle cells, mesangial cells and aortic endothelial cells (Buse, 2006). A 
study by Kolm-Litty, Sauer, Nerlich, Lehmann and Schleicher, (1998) showed that at high 
levels, D-glucosamine was more potent than D-glucose in increasing the matrix of mesangial 
cells. This is associated with an increase in TGF-P production which is converted to its active 
form TGF-P 1 and subsequent production of matrix components heparan sulphate 
proteoglycan and fibronectin. Activation of the HBP is associated with reduced insulin 
mediated translocation of GLUT-4 transporters (Marshall, Garvey, Traxinger, 1991). Some 
of the effects of the HBP in diabetes include inhibition of endothelium nitric oxide synthase 
(eNOS) through hyperglycaemia-induced O-acetyl-glucosaminylation (Brownlee, 2001). 
1.4. Diabetic complications 
1.4.1. Macrovascular complications 
Diabetes mellitus is associated with coronary, cerebral and peripheral arterial disease (Sobel 
and Schneider, 2005). Coronary and cerebral arterial diseases can result in myocardial 
infarction (MI) and stroke, respectively. These disorders, with peripheral arterial disease are 
defined as macrovascular diseases (Brownlee, 2001; Vinik and Flemmer, 2002). 
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1.4.1.1. Arterial diseases 
Arterial disease is more associated with type 2 than type 1 diabetes mellitus, because in type 
2 there is a metabolic syndrome characterised by hypertension, dyslipidaemia (increased 
triglycerides, decreased high density lipoproteins (HDL), and increased low density 
lipoproteins (LDL) and cholesterol) resulting in inflammation and impaired fibrinolysis. All 
these factors precipitate changes in the vasculature and create an environment conducive for 
accelerated atherosclerosis (Beckman, Creager and Libby, 2002; Vinik and Flemmer, 2002; 
Reusch, 2003). A greater risk to develop cardiovascular diseases, as well as increased 
morbidity and mortality is thus observed in diabetic patients due to the toxic metabolic milieu 
in the circulatory system (Beckman, Creager and Libby, 2002; Vinik and Flemmer, 2002; 
Reusch, 2003; Vinik and Vinik, 2003). The chief cause of cardiovascular disease in diabetes 
is atherosclerosis which is described below. 
1.4.1.2. Atherosclerosis 
Diabetes is associated with impaired function of the endothelium which contributes to 
atherosclerosis (Creager and Luscher, 2003). The endothelial dysfunction is due to a 
disruption of the homeostatic factors. Homeostasis is maintained through integrity of the 
endothelium barrier and a balance of the vasodilators and vasoconstrictors (Vinik and 
Flemmer, 2002; Sadeghi, 2006). The vasodilators include nitric oxide (NO), prostacyclin and 
endothelium-derived hyperpolarizing factor (EDHF) whereas the vasoconstrictors are 
endothelin-1 and angiotensin II (Brandes, Behra, Lebherz, Boger, Bode-Boger and Miigge, 
1999; Vinik and Flemmer, 2002; Creager and Luscher, 2003; Sadeghi, 2006). NO, however, 
represents a key marker in vascular health (Creager and Luscher, 2003). 
In diabetes mellitus the endothelium barrier is disrupted by the oxidative stress and increased 
activity of the metalloproteinases resulting in the entrapment of some of the excess 
atherogenic lipoproteins like very low density lipoproteins (VLDL), oxidized lipoprotein 
(oxLDL) and lipoprotein (a) (Vinik and Flemmer, 2002; Esposito, Francesco, Marfella, 
Giugliano, Giugliano, Ciotola and Quagliaro, 2002; Fan and Watanabe, 2003). This 
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infiltration triggers an inflammatory response thereby attracting monocytes and T-cells 
(Hansson, 2005; Sadeghi, 2006). The atherogenic lipoproteins also increase expression of the 
following adhesion molecules on the endothelium; the vascular cell adhesion molecule-1 
(VCAM-1) and intracellular cell adhesion molecule-1 (ICAM-1), P-selectin and E-selectin 
(Vinik and Flemmer, 2002; Esposito et ah, 2002; Fan and Watanabe, 2003; Natarajan and 
Nadler, 2004). These trigger adhesion of the attracted monocytes and T-cells to the 
endothelium. After binding to the arterial wall the monocytes and T-cells then migrate into 
the sub-endothelial space where they differentiate into macrophages and foam cells. This 
migration is attributed to chemo-attractants like oxLDL, interleukin-1 and tumor necrosis 
factor alpha (TNF-a) which are produced due to activation of the transcription factors nuclear 
factor-Kp (NF-KP) and activator protein 1 (Beckman, Creager and Libby, 2002; Esposito et 
al., 2002; Fan and Watanabe, 2003). 
The inflammatory reactions together with reduced amounts of NO precipitate atherosclerosis 
in diabetes. Reduced NO may be due to the fact that, the deformed endothelium exposes 
eNOS to uncoupling by the peroxynitrite formed from superoxide anion and nitric oxide 
making eNOS produce super oxide free radicals instead of NO (Beckman, Creager and 
Libby, 2002; Pacher, Obrosova, Mabley and Szabo, 2005). NO production may be inhibited 
by excessive liberation of free fatty acids from adipose tissue due to activation of the 
signalling enzyme protein kinase C which inhibits an eNOS agonist pathway 
phosphatidylinositol-3 (PI-3) kinase (Beckman, Creager and Libby, 2002). Thus, as NO 
bioavailability progressively decreases, concomitant increases in peroxynitrite further impair 
production of subsidiary vasodilators like the antiplatelet prostanoid prostacyclin (Beckman, 
Creager and Libby, 2002; Vinik and Flemmer, 2002; Creager and Luscher, 2003). In the 
disordered endothelium there will be, therefore, an imbalance between the vasodilators and 
vasoconstrictors with an increase in the vasoconstrictors endothelin-1 and angiotensin II. 
Vasoconstriction exacerbated by paradoxical vasoconstriction due to the effect of 
acetylcholine on smooth muscle muscarinic receptors is observed in atherosclerosis 
(Beckman, Creager and Libby, 2002; Vinik and Flemmer, 2002; Vinik and Vinik, 2003). The 
processes discussed above together with hypertension and the impaired fibrinolytic capacity 
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in the prothrombotic milieu leads to atherosclerosis in the metabolic syndrome (Beckman, 
Creager and Libby, 2002; Fan and Watanabe, 2003). 
Some of the anti-atherosclerotic drugs such as statins have been shown to lower the 
atherogenic lipoproteins and possess anti-inflammatory effects (Brandes et ah, 1999). These 
effects have also been observed with some oral anti-diabetic drugs (see pages 19-23). 
Atherosclerosis suppression also occurs with anti-diabetic plant extracts and their derivatives 
which possess anti-inflammatory and anti-hyperlipidaemic effects e.g. Tamarindus indica 
(Linnaeus) [Fabaceae], Cortex Lycii radicis (Miller) [Solanaceae] and Annona squamosa 
(Linnaeus) [Annonaceae] (Gupta, Kesari, Murthy, Chandra, Tandon and Watal, 2005; Maiti, 
Das and Ghosh, 2005; Gao, Li, Liu, Li, Liu, Fan, Li, Han and Li, 2007). Other plants contain 
derivatives with antioxidant effects, for example the dietary polyphenols and flavonoids such 
as quercetin which reduce atherogenic lipoproteins and ameliorate the oxidative stress in 
diabetes mellitus (Stoclet, Chataigneau, Ndiaye, Oak, El Bedoui, Chataigneau and Schini-
Kerth, 2004; Machha, Achike, Mustafa and Mustafa, 2007). Prevention of atherosclerosis in 
diabetes mellitus is associated with a reduction in the development of macrovascular and 
microvascular complications. 
1.4.2. Microvascular complications 
The pathogenesis of microvascular complications is similar in type 1 and type 2 diabetes 
(Sheetz and King, 2002). Microvascular complications most common in type 1 diabetes 
mellitus include retinopathy, neuropathy, and nephropathy (Gerich, 2003; Pacher, Obrosova, 
Mabley and Szabo, 2005; Waisundara, Hsu, Huang and Tan, 2008). 
1.4.2.1. Diabetic neuropathy 
Diabetic neuropathy is defined as signs and symptoms of peripheral nerve dysfunction in a 
diabetic patient where other causes of peripheral nerve dysfunction have been excluded 
(Bansal, Kalita and Misra, 2006). It is one of the commonest complications of diabetes with 
about half of the patients having some degree of the disease as polyneuropathy or 
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mononeuropathy (Sheetz and King, 2002; Tesfaye, 2003). The disease can develop in all 
types of diabetes mellitus; more in type 1 than in type 2 (Little, Edwards and Feldman, 
2007). Diabetic neuropathy leads to increased incidences of ulceration and limb amputations 
due to the irreversible progressive development of the disease, (Brown, Bird, Watling, 
Kaleta, Hayes, Eckert, Foyt, 2004; Bansal, Kalita and Misra, 2006). It accounts for silent 
myocardial infarction and shortens the lifespan of diabetic patients. The prevalence of 
diabetic neuropathy increases with the duration of the diabetic state (Bansal, Kalita and 
Misra, 2006; Little, Edwards and Feldman, 2007). 
The cause(s) of diabetic neuropathy may include any of the following; oxidative stress, 
ischaemia and inflammation leading to dysfunction and loss of axons (Little, Edwards and 
Feldman, 2007). Oxidative stress can be due to increased activity of protein kinase C. The 
blood supply to neurones may be impaired by vascular damage and endoneural hypoxia due 
to oxidative stress (Sheetz and King, 2002; Vincent, Russell, Low and Feldman, 2004). 
Hypoxia further leads to capillary damage aggravating disturbances in axonal metabolism 
and nerve conduction (Bansal, Kalita and Misra, 2006). Distal symmetrical sensorimotor 
polyneuropathy characterized by thickening of axons of small myelinated and non-
myelinated C-fibers is the most common type of diabetic neuropathy (Sheetz and King, 2002; 
Tesfaye, 2003; Bansal, Kalita and Misra, 2006; Little, Edwards and Feldman, 2007). Distal 
symmetrical sensorimotor polyneuropathy is manifested by paraesthesia, dysaesthesia, pain, 
impaired reflexes and decreased vibratory sensation (Sheetz and King, 2002; Bansal, Kalita 
and Misra, 2006). 
Inhibition of the pathways involved in the aetiology of diabetic complications in addition to 
glycaemic control, antidepressants and analgesics may be used to manage diabetic 
neuropathy (Vincent, Russell, Low and Feldman, 2004; Wong, Chung and Wong, 2007). 
Studies indicate that plant derivatives such as alpha-lipoic acid, primrose oil and capsaicin 
have potential in the management of diabetic neuropathy (Halat and Denneby, 2003). With 
respect to the focus of this study, diabetic neuropathy influences renal function via changes 
in sympathetic input to various parts of the nephron, thereby modulating renin secretion and 
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the renal tubular reabsorption of sodium and water (Di Bona, 1985). Such a relationship may 
be a potential target for drugs or medicinal plants that alleviate diabetic nephropathy. 
1.4.2.2. Diabetic retinopathy 
Diabetic retinopathy due to damage of the blood vessels of the retina, is the most common 
cause of blindness in diabetic patients (Khan and Chakrabarti, 2007; Kowluru and Chan, 
2007). Nearly all people with type 1 and more than half with type 2 diabetes develop 
retinopathy 15-20 years after diagnosis (Williams, Airey, Baxter, Forrester, Kennedy-Martin 
and Girach, 2004). Retinal complications in chronic diabetes may culminate from 
microvascular dysfunction, neuroglial abnormalities, and the toxic metabolic environment 
(Khan and Chakrabarti, 2007). Diabetic retinopathy is a duration-dependent disease that 
develops in stages and which may not be detected in the first few years of diabetes (Kowluru 
and Chan, 2007). 
Diabetic retinopathy can be described as non-proliferative diabetic retinopathy (NPDR) and 
proliferative diabetic retinopathy (Khan and Chakrabarti, 2007; Williams et al., 2004). 
Additionally NPDR has further been divided in progressive stages: mild, moderate and 
severe (Khan and Chakrabarti, 2007; Kowluru and Chan, 2007). NPDR is characterized by 
capillary basement membrane thickening, pericyte loss, micro-aneurysms, increased 
permeability, exudates deposits, and retinal micro-infarcts. The earliest sign of retinal 
damage during NDPR results from abnormal permeability and non-perfusion of capillaries, 
leading to the formation of micro-aneurysms. Visual acuity is impaired by macular oedema, 
following the leakage of fluid and solutes into the surrounding retinal tissue (Williams et al., 
2004). The later stages, sometimes called pre-proliferative retinopathy, show increased 
retinal damage as evidenced by increased retinal vascular blockage and infarcts. Proliferative 
retinopathy develops if the pre-proliferative retinopathy is not treated. This is characterized 
by abnormal proliferation of blood vessels on the retina. These vessels, however, are fragile 
and haemorrhage easily. The resulting accumulation of blood in the vitreous humour from 
these haemorrhaging vessels impairs vision; this impairment can be permanent due to 
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complications such as retinal detachment (Khan and Chakrabarti, 2007; Williams et al., 
2004). 
The pathways previously described (see section 1.3) lead to the structural and functional 
changes that occur in diabetes mellitus, particularly the aldose reductase pathway (Khan and 
Chakrabarti, 2007). Diabetic retinopathy, like most other complications of diabetes mellitus, 
does not usually occur in isolation in the diabetic state. Therefore, drugs and medicinal plants 
that are used to inhibit the pathways involved in the development of diabetic complications 
may also prevent development of diabetic retinopathy (see section 1.3). 
1.4.2.3. Diabetic nephropathy 
Diabetic nephropathy a leading cause of end-stage renal disorder (ESRD), accounts for 
significant morbidity and mortality in diabetes (Mogensen, 2003; Schena and Gesualdo, 
2005; Sarafidis, 2007; Bloomgarden, 2008). The pathophysiology of diabetic nephropathy 
involves interactions between the metabolic and haemodynamic factors. Some of the 
metabolic factors include increased formation of AGE's, polyols and activation of protein 
kinase C (Cooper, Gilbert and Epstein, 1998; Rao and Nammi, 2006). The involvement of 
these pathways in the development of diabetic nephropathy has been described above in 
section 1.3. Haemodynamic factors include systemic hypertension and the tone of both 
afferent and efferent arterioles (Cooper, Gilbert and Epstein, 1998). Diabetic nephropathy 
progresses from microalbuminuria to overt proteinuria and then renal failure. In the initial 
stages of diabetes, there is enlargement of the kidneys and increased glomerular filtration rate 
(GFR), then progressively the GFR decreases (Thomson, Vallon and Blantz, 2004; Rao and 
Nammi, 2006). The two main hypotheses that describe the initial events of diabetic 
nephropathy are the 'vascular hypothesis' and the 'tubular hypothesis' (Zerbini, Bonfanti, 
Meschi, Bognetti, Paesano, Gianolli, Querques, Maestroni, Calori, Maschio, Fazio, Luzi and 
Chiumello, 2006). The vascular hypothesis states that the initial hyperfiltration is due to an 
excessive production of vasodilator products like nitric oxide and prostaglandins and the 
increased osmolar load (Vinik and Vinik, 2003). Additionally, there is increased glomerular 
hydrostatic pressure associated with microalbuminuria (Mason and Wahab, 2003; Kumar, 
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Shetty and Salimath, 2008). These features result in basement membrane thickening, 
mesangial proliferation, and glomerulosclerosis as a compensatory mechanism to prevent 
electrolyte loss. In contrast, the tubular hypothesis contends that hyperglycaemia induces 
increased production of growth factors and cytokines which cause hyperplasia and 
hypertrophy of the nephron, particularly the proximal tubule (Zerbini et al., 2006). As a 
result increased reabsorption of sodium occurs in the proximal tubule, consequently reducing 
the sodium load to the macula densa (Zerbini et al., 2006). In experimental animals, it is, 
suggested that the vascular hypothesis is more applicable considering that the hyperfiltration 
is observed within 24 hours of diabetes induction. 
The hypertrophy of the nephron in diabetic nephropathy occurs because of excessive 
deposition of extra cellular matrix proteins involved in the architecture of glomerular 
basement membrane (GBM). These include multifunctional glycoproteins, laminin, 
fibronectin and type IV collagen. At the same time, there is a decrease in production and 
under-sulphation of heparan sulphate proteoglycan. This enhances the permeability to 
macromolecules since the glycoproteins and heparan sulphate proteoglycan normally interact 
to form a barrier to charged molecules (Kumar, Shetty and Salimath, 2008). Some anti-
diabetic plants, such as Momordica charantia (Linnaeus) [Curcubitaceae], have been shown 
to improve renal function and to delay the onset of diabetic nephropathy by preventing the 
decrease in heparan sulphate and its under-sulphation (Kumar, Shetty and Salimath, 2008). 
Endothelin-1 (ET-1), which increases five-fold in diabetic animal models has been 
implicated in causing glomerular hypertrophy mediated by TGF-pV Indeed, experimental 
evidence indicates that inhibition of ET-1 and TGF- Pi and the endothelin-1 receptor A 
(ETRA) with plant extracts improves renal function and ameliorates glomerular injury 
(Khan, Farhangkhoee, Mahon, Bere, Gonder, Chan, Uniyal and Chakrabarti, 1999; Hargrove, 
Dufresne, Whiteside, Muruve, and Wong, 2000; Sorokin and Kohan, 2003; Nakagawa, Goto, 
Hikiami, Yokozawa, Shibahara and Shimada, 2007). The production of ET-1 is augmented 
by vasoconstrictor, profibrotic and inflammatory substances, all of which are increased in 
hyperglycaemic conditions. Additionally the activation of PKC favours ET-1 production, as 
this is the signalling pathway leading to up regulation of this hormone (Sorokin and Kohan, 
2003). The effects of ET-1 are mainly directed at mesangial cells, and the proliferation of 
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these cells is due to direct or indirect stimulation of their mitogenesis (Sorokin and Kohan, 
2003). 
Irrespective of all the other structural and functional changes, the mesangial alterations 
appear to be the main cause of declining renal function in experimental diabetic animal 
models (Gnudi, Viberti, Raij, Rodriguez, Burt, Cortes, Hartley, Thomas, Maestrini and 
Gruden, 2003; Mason and Wahab, 2003; Kumar, Shetty and Salimath, 2008). Hyperfiltration 
can be attributed to increased production of the vascular permeability factor in response to 
stretching in the mesangium (Gruden, Thomas, Burt, Lane, Chusney, Sacks and Viberti, 
1997). The decline in glomerular filtration rate is due to the expanded extracellular mesangial 
matrix which compresses the glomerular capillaries thereby reducing the filtration surface 
area (Gnudi et al, 2003; Mason and Wahab, 2003; Kumar, Shetty and Salimath, 2008). The 
mesangial cells have also been shown to increase glucose uptake through the increased 
expression of GLUT-1 transporters (Schena and Gesualdo, 2005; Gnudi, Thomas and 
Viberti, 2007). Increased glucose uptake exacerbates intracellular hyperglycaemia and 
increased activity in the previously described pathways (see section 1.3.). 
The increased levels of endothelin-1 and angiotensin II in diabetes mellitus lead to 
development of systemic and intrarenal hypertension (Vinik and Vinik, 2003). An enhanced 
tubuloglomerular feedback characterized by reduced sodium excretion in the kidney is the 
compensatory response to the elevated blood pressure (Zerbini et al., 2006; Oh, Joo, Lee, 
Jeon, Lim, Han, Knepper and Na, 2007). Against this background are observations that mean 
arterial pressure (MAP) is not altered in experimental diabetic animals despite showing 
impaired fluid and electrolyte handling (Musabayane, Ndhlovu and Balment, 1995). 
Several plants which include Sclerocarya birrea [(A. Rich) Hochst.] [Anachardiaceae], 
Persea americana (Miller) [Lauraceae] and Ficus thonningii (Blume) [Moraceae] have been 
shown to possess reno-protective effects (Musabayane, Gondwe, Kamadyaapa, Churtugoon 
and Ojewole, 2007; Gondwe, Kamadyaapa, Tufts, Chuturgoon and Musabayane, 2008 and 
Gondwe, Kamadyaapa, Tufts, Chuturgoon, Ojewole and Musabayane, 2008). For instance 
studies indicate that Cornus officinalis [Sieb et. Zucc] inhibits AGE formation and decreases 
16 
levels of RAGE (Yokozawa, Yamabe, Kim, Kang, Hur, Park, Tanaka, 2008). Polyphenols 
isolated from Vigna angularis [(Willdenow Ohwi & H. Ohashi)] [Fabaceae] were shown to 
attenuate glomerular expansion in STZ-induced diabetic rats, as well as suppressing the 
number of infiltrating macrophages (Sato, Yamate, Hori, Hatai, Nozawa and Sagai, 2005). 
Some plant extracts may, however, further compromise kidney function in diabetes mellitus 
by impairing renal fluid and electrolyte handling (Musabayane, Xozwa and Ojewole, 2005). 
1.5. Diabetes management 
Discussions in the preceding paragraphs indicate that hyperglycaemia is associated with 
impaired kidney and cardiovascular functions. The goal in the management of diabetes 
mellitus should, therefore, be to achieve near normal or improved glycaemia control to 
diminish the risk of long-term diabetic complications (DeFronzo, 1999; Robertson, Drexler 
and Vernillo, 2003; Krentz and Bailey, 2005; Yurgin, Secnik and Lage, 2008). The 
importance of blood glucose control in preventing microvascular complications of diabetes 
mellitus is now well recognized and the treatment regimen incorporates a controlled-energy 
diet, regular aerobic exercises and weight loss (Inzucchi, 2002; The Diabetes Control and 
Complications Trial Research Group (DCCT), 1993; Robertson, Drexler and Vernillo, 2003; 
Krentz And Bailey, 2005; Paterson, Rutledge, Cleary, Lachin and Crow, 2007; Holman, 
Paul, Bethel, Matthews and Neil, 2008). This, however, should include pharmacotherapy, 
since most patients fail to achieve adequate blood glucose control with lifestyle interventions 
alone (Inzucchi, 2002; Fowler, 2007) (see pages 18-24 below on pharmacotherapy). There 
are many standard anti-diabetic drugs used in the management of diabetes mellitus. These 
include various formulations of insulin and oral anti-diabetic agents which can be used as 
monotherapy or in combination to achieve better glycaemic regulation (Robertson, Drexler 
and Vernillo, 2003; Jung et al., 2006). The oral anti-diabetic agents such as metformin with 
insulin, sulphonylureas and thiazolidinediones have been found to be more effective when 
used in combination than when singly administered. Indeed, single therapy has been found to 
be ineffective in maintaining normoglycaemia particularly as diabetes progresses 
(Kirpichnikov, McFarlane, Sowers, 2002; Krentz and Bailey, 2005). Recently, a 'polypill' 
treatment was suggested as a potential overall remedy for diabetes and its complications 
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(Gershell, 2005; Grundy, 2006). This combination pill includes an anti-hyperglycaemic, anti-
inflammatory, anti-hypertensive, and anti-angiogenic agent. According to Krentz and Bailey, 
(2005), the anti-diabetic drugs can be classified as insulin secretagogues, insulin sensitizers 
and those that delay carbohydrate absorption. In addition to the use of synthetic drugs 
medicinal plants and their derivatives are also used in the management of diabetes mellitus. 
The following sections discuss the anti-diabetic mechanisms of the synthetic drugs and some 
of the medicinal plants. 
1.5.1. Insulin 
Insulin, discovered in 1921, is the major current hypoglycaemic agent used in the 
management of type 1 diabetes and late stage type 2 diabetes (Emilien, Maloteaux and 
Ponchon, 1999). Patients who do not achieve effective glycaemic control with oral agents or 
for whom other oral agents are contraindicated are also treated with insulin (Laube, 2002; 
Krentz and Bailey, 2005). Robertson, Drexler and Vernillo, (2003) classify insulin as human 
insulin and insulin analogues. Another form of classification based on the duration of action 
gives four main types; rapid-acting, short-acting, intermediate-acting and long-acting 
(Vazquez-Carrera and Silvestre, 2004; Bethel and Feinglos, 2005). 
The short acting types have been designed to mimic bolus insulin secretion, while 
intermediate or long acting insulin analogues are designed to mimic basal glycaemic control 
(Vazquez-Carrera and Silvestre, 2004; Fonseca, 2006). Insulin is administered 
subcutaneously using multiple daily injections, or an external pump for continuous delivery 
(Hirsch, Bode, Garg, Lane, Sussman, Hu, Santiago and Kolaczynski, Insulin Aspart 
CSII/MDI Comparison Study Group, 2005). Other delivery routes include oral, inhaled, 
nasal, rectal, ocular, intravaginal and transdermal (Grover, Vats and Rathi, 2000; Takei and 
Kasatani, 2004). The disadvantages of insulin use include short shelf life, severe 
hypoglycaemia with overdosage, pain with subcutaneous injection and weight gain. A 
combination of insulin with oral anti-diabetic drugs has been shown to reduce some of these 
disadvantages, for example weight gain (DeFronzo, 1999; Robertson, Drexler and Vernillo, 
2003; Takei and Kasatani, 2004; Laube, 2002; Massi-Benedetti and Orsini-Federici, 2008). 
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1.5.1.1. Insulin-like medicinal plants 
Olea europaea (Linnaeus) [Oleaceae] fruit has been shown to increase glycogen 
concentration by inhibiting glycogen phosphorylase activity (Chen, Liu, Zhang, Wu, Hua, 
Wu and Sun, 2006). Puerarin, an isoflavone derived from the roots of Pueraria lobata 
(Willdenow Ohwi) [Fabaceae] has been shown to increase translocation of GLUT-4 
transporters in the absence of insulin in isolated soleus muscles (Hsu, Liu, Kuo, Chen, Su and 
Cheng, 2003). Extracts of Bauhinia candicans (Benthamantha) [Caesalpiniaceae] and 
procyanidins from Vitis vinifera (Linnaeus) [Vitaceae] seeds have been shown to have 
insulin-mimetic effects on glucose uptake in insulin sensitive cell lines thereby increasing 
peripheral glucose utilization (Pinent, Blay, Blade, Salvado, Arola and Arde, 2004; Fuentes 
and Alarcon, 2006). Maiti, Das and Ghosh, (2005) showed that the aqueous extract of the 
seed of Tamarindus indica (Linnaeus) [Fabaceae] reduced blood glucose levels by increasing 
hepatic glycogen concentrations. 
1.5.2. Insulin sensitizers 
1.5.2.1. Biguanides 
Phenformin (phenethylbiguanide) and metformin (1,1 dimethylbiguanide hydrochloride) are 
examples of biguanides. Metformin was derived from Galega officinalis (Linnaeus) 
[Fabaceae] (French lilac), a plant rich in biguanides (Grover, Yadav and Vats, 2002; Krentz 
and Bailey, 2005; Modak, Dixit, Londhe, Ghaskadbi and Devasagayam, 2007). Metformin 
can be used alone or in combination with other drugs like sulphonylureas in diabetes 
management (Bailey, Path and Turner, 1996). Despite the mechanisms of the hypoglycaemic 
effects of biguanides being unclear, the end result is that they increase insulin sensitivity in 
type 2 diabetes (Bailey, Path and Turner, 1996) perhaps by enhancing insulin effects. It is 
known that the lowering of blood glucose by metformin not only involves suppression of 
gluconeogenesis and glycogenolysis, but also enhancement of insulin-stimulated glucose 
uptake in skeletal muscles (Rendell, 2004; Krentz and Bailey, 2005; Ajjan and Grant, 2006). 
Studies indicate that metformin activates 5AMP-activated protein kinase (AMPK), a 
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heterotrimeric enzyme composed of a catalytic subunit (a) and two regulatory subunits (P 
and y) (Ubl, Chen and Stucki, 1994; Krentz and Bailey, 2005). There are two isoforms of the 
catalytic subunit: AMPK al, which is widely distributed, and AMPK a2, which is expressed 
in skeletal muscle, heart, and liver (Fryer, Parbu-Patel and Carling, 2002; Musi, Hirshman, 
Nygren, Svanfeldt, Bavenholm, Rooyackers, Zhou, Williamson, Ljunqvist, Efendic, Moller, 
Thorell, and Goodyear, 2002). Previous studies have shown that AMPK is activated 
following depletion of cellular ATP resulting in phosphorylation of AMPK to prevent 
breakdown of carbohydrates (Fryer, Parbu-Patel and Carling, 2002). The increase in AMPK 
activity results in the stimulation of glucose uptake in cells and the inhibition of hepatic 
glucose production, cholesterol and triglyceride synthesis, and lipogenesis (Musi et ah, 2002; 
Krentz and Bailey, 2005). Metformin also lowers blood glucose concentrations by decreasing 
intestinal absorption of glucose (Kirpichnikov, McFarlane and Sowers, 2002). Novel 
antihyperglycaemic mechanisms of metformin have been reported to involve enhancement of 
beta P-endorphin secretion from adrenal glands and stimulating opioid u-receptors located in 
peripheral tissues. The stimulation of the opioid u-receptors increases GLUT-4 transporters 
(Cheng, Huang, Liu, Tzeng and Chang, 2006). 
The efficacy of glycaemic control achieved with metformin is similar to that achieved with 
sulphonylureas, although their modes of action differ. Metformin has beneficial effects on 
several cardiovascular risk factors (Krentz and Bailey, 2005). Furthermore, beneficial effects 
of metformin in type 2 diabetes, include weight reduction, improved lipid profiles, and 
enhanced endothelial function (Cheng, Huang, Liu, Tzeng and Chang, 2006; Skaer, Sclar, 
Robinson, 2006). The use of metformin, however, is contraindicated in conditions such as 
hypoxia, reduced perfusion of the heart in respiratory insufficiency and impaired renal 
function (Krentz and Bailey, 2005). 
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1.5.2.2. Plant insulin sensitizers 
Some bioactive compounds have been shown to improve insulin sensitivity by primarily 
facilitating GLUT-4 translocation. Examples are flavonoids from Cephalotaxus sinensis 
[(Rehder & E.H. Wilson) H. L. Li] [Cephalotaxaceae] (Li, Dai, Yu, Li, Wu, Luan, Meng, 
Zhang and Deng, 2007). Punica granatum (Linnaeus) [Lythraceae] has been shown to 
enhance insulin secretion by increasing the number of pancreatic P-cells (Katz, Newman and 
Lansky, 2007). Jung, Ha, Shim, Choi, Yun-Choi and Lee, (2007) showed that Campsis 
grandiflora (K. Schumann) [Bignoniaceae] enhanced the effects of insulin on the signalling 
of the insulin receptor (IR). This was associated with an increase in insulin-mediated tyrosine 
autophosphorylation of the IR-|3 subunit as well as GLUT-4 translocation. 
1.5.2.3. Thiazolidinediones 
Thiazolidinediones (TZDs), troglitazone, pioglitazone and rosiglitazone are selective and 
potent agonists of peroxisome proliferator-activated receptor (PPAR)-y (Chiarelli and Di 
Marzio, 2008). PPAR-y and its isoforms PPAR-a and PPAR-5, are members of the nuclear 
hormone receptors (Beckman, Creager and Libby, 2002; Kudzma, 2002; Chiarelli and Di 
Marzio, 2008). PPAR-y receptors are found on insulin-sensitive tissues where they act as 
lipid sensors and regulate carbohydrate and lipid metabolism. Upon activation of PPAR-y 
there is an improvement in insulin sensitivity thereby increasing glucose uptake in the 
skeletal muscles and reducing hepatic glucose output (Beckman, Creager and Libby, 2002; 
Kudzma, 2002; Chiarelli and Di Marzio, 2008). This effect has been attributed to be the 
cause of TZDs' ability to protect pancreatic P-cell function (Kudzma, 2002; Ajjan and Grant, 
2006; Chiarelli and Di Marzio, 2008). TZDs have also been shown to modulate most risk 
factors for cardiovascular diseases (Kudzma, 2002; Krentz and Bailey, 2005). They modify 
lipid profiles, lowering blood pressure and prevent inflammation and atherosclerosis in 
vascular tissues (Kudzma, 2002). 
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1.5.2.4. Plant PPAR agonists 
A study by Han, Choi, Lee, Song, Joe, Jung, and Hwang, (2008), showed that macelignan 
derived from Myristica fragrans (Gronov.) [Myrsticaceae] exerted anti-diabetic effects 
through dual activation of peroxisome proliferator activated receptors-a/y in obese diabetic 
mice. In vivo and in vitro studies have shown that dietary soy isoflavones improve lipid 
metabolism and reduce blood glucose levels through activation of the PPAR receptors 
(Mezei, Banz, Steger, Peluso, Winters and Shay, 2003). 
1.5.3. Insulin secretagogues 
1.5.3.1. Sulphonylureas 
The drugs in the sulphonylurea group include glibenclamide, chlopropamide, tolbutamide 
and gliclazide. Sulphonylureas (SUs) augment glucose-induced insulin release from the [3-
cells of the pancreas (Dhindsa, Davis and Donnelly, 2002; Krentz and Bailey, 2005). They 
block the opening of potassium channels (KATP) by binding to the pancreatic P-cell 
sulphonylurea receptors (SUR)l and depolarise the membrane leading to calcium influx 
through opened voltage gated calcium channels (Rendell, 2004; Krentz and Bailey, 2005). 
Increased intracellular calcium levels mobilise calcium dependant insulin vesicles to fuse 
with the membrane and release insulin (Krentz and Bailey, 2005; Ajjan and Grant, 2006). 
SUR1 is the regulatory subunit on P-cell KATP channels whereas variants of SUR2 are on 
KATP channels of cardiac (SUR2A) and vascular smooth muscles (SUR2B) (Dhindsa, Davis 
and Donnelly, 2002). Tolbutamide and gliclazide block the SUR1 subunit, whereas 
glibenclamide and glimepiride have affinity for both SUR1 and SUR2 isoforms (Dhindsa, 
Davis and Donnelly, 2002). The binding of SUs to KATP channels of coronary vessels causes 
dilatation to enable the heart to adapt in ischaemic conditions (Ajjan and Grant, 2006). 
Sulphonylureas can cause hypoglycaemia for the release of insulin is initiated even when 
glucose concentrations are below the normal threshold for the release of the peptide (Krentz 
and Bailey, 2005). 
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1.5.3.2. Meglitinides 
Meglitinides which include repaglinide and nateglinide enhance the initial surge of insulin 
release in response to meals by binding to specific SUR1 sites on pancreatic p-cell 
membranes (Gerich, 2003; Krentz and Bailey, 2005). Activity of meglitinides depends on the 
concentration of the blood glucose and the dose of the drug used (Gerich, 2003). The drugs 
are taken prior to meals to prevent postprandial hyperglycaemia because they have a short 
half life (Krentz and Bailey, 2005). 
1.5.3.3. Plant insulin secretagogues 
The aqueous extract of Scoparia dulcis (Linnaeus) [Scrophulariaceae] (Sweet broomweed) 
has been shown to increase insulin secretion in isolated pancreatic islet P-cells (Latha, Pari, 
Sitasawad and Bhonde, 2004). Similar effects were reported with various medicinal plants 
like Viscum album (Linnaeus) [Lorantaceae], Sambucus nigra (Linnaeus) [Adoxaceae] 
(elder) and Smallanthus sonchifolius [(Poepigg and Andlicher) H. Robinson] [Asteraceae] 
(yacon) (Gray and Flatt, 1999; Gray, Abdel-Wahab and Flatt, 2000; Aybar, Riera, Grau and 
Sanchez, 2001). Some bioactive compounds isolated from anti-diabetic plant extracts have 
also been shown to stimulate insulin secretion in vitro (Jayaprakasam, Vareed, Olson and 
Nair, 2005). An example is phanoside, a gypenoside isolated from Gynostemma 
pentaphyllum (Thunb. Makino) [Cucurbitaceae] which acts distal to the KATP and L-type 
calcium channels on the exocytotic machinery (Hoa, Norberg, Sillard, Van Phan, Thuan, 
Dzung, Jornvall and Ostenson, 2004; 2007). Asparagus racemosus (Willdenow) 
[Asparagaceae] root extracts have been shown to increase insulin secretion in isolated P-cells 
and perfused pancreas via the cyclic adenosine monophosphate (cAMP) pathway (Hannan, 
Marenah, Ali, Rokeya, Flatt and Abdel-Wahab, 2007). 
1. 5.4. a-Glucosidase inhibitors 
a-Glucosidase inhibitor drugs such as acarbose, miglitol and voglibose inhibit intestinal 
glucose absorption (Krentz and Bailey, 2005; Ajjan and Grant, 2006; Modak, Dixit, Londhe, 
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Ghaskadbi and Devasagayam, 2007). a-Glucosidase a membrane-bound enzyme on the 
epithelium of the small intestine hydrolyses disaccharides and oligosaccharides (AH, 
Jahangir, Hussan and Choudhary, 2002). Inhibition of a-glucosidase prevents a postprandial 
increase in blood glucose concentration due to delayed carbohydrate absorption (Ajjan and 
Grant, 2006). Acarbose has also been shown to increase the secretion of glucagon-like 
peptide (GLP)-l, although the relative contribution of this effect to the reduction in 
postprandial hyperglycaemia is unknown (Gerich, 2003). 
1.5.4.1. a-Glucosidase inhibiting plants 
Various medicinal plant extracts have been shown to lower blood glucose concentrations 
through inhibition of the a-glucosidase enzyme. The extracts include those from Pinus 
densiflora (Siebold and Zuccarini) [Pinaceae], Syzygium cumini (Linnaeus Skeels) 
[Myrtaceae], Actinidia deliciosa (C.F. Liang & A.R. Ferguson) [Actinidiaceae], Malmea 
depressa (Baillon) R.E. Fries [Annonaceae] and Punica granatum (Linnaeus) [Lythraceae]. 
Most of the plants that inhibit a-glucosidase have also been shown to inhibit a-amylase 
(Kim, Wang and Rhee, 2004; Li, Wen, Kota, Peng, Li, Yamahara and Roufogalis, 2005; 
Andrade-Cetto, Becerra-Jimenez and Cardenas-Vazquez, 2008; Shinde, Taldone, Barletta, 
Kunaparaju, Hu, Kumar, Placido and Zito, 2008; Shirosaki, Koyama and Yazawa, 2008; 
Subramanian, Asmawi and Sadikun, 2008). The discussion in the preceding sections 
highlights blood glucose lowering effects of some synthetic anti-diabetic agents and plant 
derived extracts/agents. On this basis this study investigated the potential of a bioactive plant 
extract in diabetes mellitus management. 
1.6. Traditional (indigenous/folk) medicine 
Traditional medicine predominant in developing countries is established knowledge systems 
incorporating plant, animal and mineral-based medicines (Gilani and Rahman, 2005; 
Stangeland, Dhillion and Reksten, 2008). Examples of such systems include traditional 
African medicine, Chinese medicine, Indian ayurveda and Arabic unani medicine. In the sub-
Saharan African region the majority of the population rely on traditional medicine (WHO 
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traditional medicine (WHO Report, 2002-2005). This is attributed to limited resources and 
poor access to modern health care systems, in contrast to traditional medicine which is easily 
available and affordable (WHO Expert Committee on Diabetes, 1980; WHO Report, 2002-
2005). Plants have always been a source of drugs and many of the currently available drugs 
have been derived directly or indirectly from plant extracts (Gurib-Fakim, 2006). Drugs like 
aspirin, digoxin, ephedrine, reserpine and tubocurarine, in use today, were derived from 
plants (Stangeland, Dhillion and Reksten, 2008). The use of medicinal plants is also based on 
the belief that they have fewer side effects as compared to allopathic drugs (Maries and 
Farnsworth, 1994; Kim, Kang, Park, Jung, Choi and Ku, 2007b). Various disorders managed 
with medicinal plant extracts include diabetes mellitus, ulcers, cancers, cardiac diseases, 
renal diseases and some infectious diseases (Liu, 1995; Jouad, Haloui, Rhiouani, Hilaly and 
Eddouks, 2001). 
1.6.1. Plant based management of diabetes mellitus 
Diabetes mellitus is expected to increase the burden on health systems in the future, not only 
because of the absence of a known cure, but also due to its high prevalence and associated 
complications (Sobngwi, Mauvais-Jarvis, Vexiau, Mbanya and Gautier, 2001; Vinik and 
Vinik, 2003). Current conventional diabetes therapy using blood glucose-lowering 
medications such as insulin or oral hypoglycaemic agents has limitations. Alternative 
methods of lowering blood glucose are, therefore, needed. Herbal medicines have been used 
for many years by different cultures around the world, both for the prevention and 
management of diabetes mellitus (Jung et ah, 2006; Kim et al., 2007b). Scientific 
investigations have established the potential of plant extracts in the management of diabetes 
mellitus and alleviation of associated complications (Maries and Farnsworth, 1994; Wang 
and Ng, 1999; Sharma, Nasir, Prabhu, Murthy and Dev, 2003; Li et al, 2007). Indeed, 
extracts of Trichosanthis radix (Maximowicz) [Curcubitaceae], Garcinia kola (Heckel) 
[Clusiaceae], Opunthia megacantha (Miller) [Cactaceae], Allium sativum (Linnaeus) 
[Alliaceae], Punica granatum (Linnaeus) [Lythraceae] and Syzygium aromaticum 
[(Linnaeus) Merrill & Perry] [Myrtaceae] possess anti-diabetic properties (Bwititi and 
Musabayane, 1997; Bwititi, Musabayane and Nhachi, 2000; Adaramoye and Adeyemi, 2006; 
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Wei-ha et al., 2008). The multiple beneficial activities like manipulating carbohydrate 
metabolism, and preventing and restoring integrity and function of P-cells suggest that 
medicinal plant extracts offer a useful source of hypoglycaemic drugs (Tiwari and Rao, 
2002). Metformin was derived from the traditional approach of using the guanidine-rich 
Galega officinalis (Linnaeus) [Fabaceae] (French lilac) to treat diabetes mellitus (Parturier, 
1957; Grover, Yadav and Vats, 2002; Krentz and Bailey, 2005; Modak, Dixit, Londhe, 
Ghaskadbi and Devasagayam, 2007). Bioactive compounds with hypoglycaemic effects 
isolated from plants include polysaccharides, flavonoids, xanthones, peptides and 
triterpenoids (Wang and Ng, 1999; Grover, Yadav and Vats, 2007). 
Most of the work in our laboratory thus far has investigated the blood glucose lowering 
effects of crude plant extracts. The World Health Organisation recommends scientific 
evaluation of anti-diabetic plants and their bioactive compounds. Despite this, the 
establishment of the mechanisms through which medicinal plants exert their hypoglycaemic 
effects and proper scientific screening has been done for only a few ethnomedicinal plants. 
Scientific evaluation of ethnomedicinal plants may pave way for the discovery of natural 
products for developing new anti-diabetic drugs (Pushparaj, Tan and Tan, 2001; Sharma, 
Nasir, Prabhu, Murthy and Dev, 2003; Jung et al., 2006). The bioactive compound of interest 
in this study was from Syzygium cordatum (Hochst.) [Myrtaceae]. Preliminary studies 
indicated that the crude extracts lowered blood glucose concentrations (Musabayane, 
Mahlalela, Shode and Ojewole, 2005). Compounds isolated from S. cordatum plant parts 
include pentacyclic triterpenoids (Candy, McGarry and Pegel, 1968; Bruneton, 1995) 
1.6.2. Syzygium cordatum (Hochst.) [Myrtaceae] 
S. cordatum an evergreen tree, grows to a height of 8-15meters along stream banks, on forest 
margins or in swampy spots from KwaZulu-Natal northwards to Zimbabwe and Mozambique 
(Van Wky, Van Oudtdhoorn and Gericke, 1997). The leaves are elliptic to circular, bluish 
green on top and a paler green below. The fruits (Figure 1) are oval berries, red to dark-
purple when ripe with a slightly acidic taste. S. cordatum tree is known for its many uses. 
The fleshy fruit is used sometimes to make an alcoholic drink. The powdered bark is used as 
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a fish poison. In central Africa, the tree is used to treat stomach aches, diarrhoea, respiratory 
ailments and tuberculosis (Watt and Breyer-Brandwijk, 1962; Iwu, 1993). The crude leaf 
extract of S. cordatum has been shown to possess hypoglycaemic properties and increase 
muscle and hepatic glycogen concentrations (Musabayane, Mahlalela, Shode and Ojewole, 
2005). The antihyperglycaemic effect of the leaf extract was attributed to its triterpenoid 
constituents which are discussed in the next section. 
1.6.3. Triterpenoids 
The triterpenoids are molecular structures with four or five rings composed of 30 carbon 
atoms formed by cyclization of squalene (Stangeland, Dhillion and Reksten, 2008) (see 
Figure 5 on page 49). Triterpenoids include oleanolic acid, maslinic acid, gallic acid, 
corosolic acid and ursolic acid (Liu, 1995; Shishodia, Majumdar, Banerjee and Aggarwal, 
2003; Dzubak, Hajduch, Vydra, Hustova, Kvasnica, Biedermann, Markova, Urban and 
Sarek, 2006). Triterpenoids exist in food and medicinal herbs as free acids (aglycone or 
genin) or attached to carbohydrate residues, saponins or glycosides (Liu, 1995; Choi, You 
and Jeong, 2001). The triterpenoids can be classified in relation to the triterpene class 
(oleanane group), herbs that contain them (platycodon) and by therapeutic action (antitumor) 
(Connolly and Hill, 2002). The occurrences of the acids vary within the same plant and in 
different plants (Dzubak et ah, 2006). 
The triterpenoids have a range of unique and potentially usable biological effects like anti-
inflammatory, antitumor, anti-diabetic, antihypertensive and antimicrobial activity with 
varying potencies (Ghosh, Thejomoorthy and Veluchamy, 1981; Liu, 1995; Somova, Nadar, 
Ramnanan and Shode, 2003; Dzubak et ah, 2006; Lee, Nam, Kim and Lee, 2006; Jung et ah, 
2007). The variations in the potencies are attributed to the different structures, such as the 
number of the hydroxyl groups. Thus, the pharmacokinetic and pharmacodynamic properties 
of the acids and ultimately the bioavailability and the biological effects are influenced by the 
structure of the acids (Liu, 2005; Jung et ah, 2007). Triterpenoids have been identified as the 
major components of many traditional medicinal plants and, therefore, a lot of interest has 
grown in elucidation of their biological roles (Choi, You and Jeong, 2001). 
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Figure 1 S. cordatum tree (A) and the fruit and leaves (B) 
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1.7. Basis of the present study 
The previously reported antihyperglycaemic effect of crude S. cordatum leaf extract has been 
attributed to its triterpenoid constituents. Oleanolic acid (OA) is the most abundant triterpene 
from most medicinal plants. This study was, therefore, designed to isolate and investigate the 
acute and short-term term effects of oleanolic acid derived from S. cordatum on blood 
glucose, renal function and mean arterial blood pressure in streptozotocin (STZ)-induced 
diabetic rats. 
1.7.1. Hypothesis 
S. cordatum derived oleanolic acid possesses anti-hyperglycaemic and reno-protective effects 
in STZ-induced diabetic rats. 
1.7.2. Aims 
The overall aim was to study the anti-hyperglycaemic and renal effects of S. cordatum 
derived oleanolic acid in STZ-diabetic rats. 
The specific research objectives were to: 
a) isolate the oleanolic acid from S. cordatum leaves. 
b) investigate the acute {VA h) and short-term (5-weeks) effects of the oleanolic acid on 
blood glucose concentration in STZ-induced diabetic rats and compare them to those 
of allopathic anti-diabetic drugs. 
c) investigate the combined effects of the oleanolic acid with allopathic anti-diabetic 
drugs on blood glucose concentration in STZ-induced diabetic rats. 
d) investigate the acute (1XA h) effects of the oleanolic acid on renal fluid and electrolyte 
handling and blood pressure in STZ-induced diabetic rats. 
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CHAPTER 2 
2.0. MATERIALS AND METHODS 
2.1. Ethical consideration 
Ethical clearance was obtained from the University of KwaZulu-NataPs Ethics 
committee (reference 037/07 Animal and 048/08 Animal, see Appendices I and II). 
2.2. Materials 
2.2.1. Drugs and chemicals 
Drugs and chemicals were sourced as indicated: glibenclamide (glyburide; N-p-[2-(5-
chloro-2-methoxybenzamido] ethylbenzene-sulfonyl-jV'-cyclohexylurea), metformin (1,1-
dimethylbiguanide hydrochloride), streptozotocin, dimethyl sulphoxide (DMSO), inactin 
(5-ethyl-5-(l'-methylpropyl)-2-thiobarbiturate) (Sigma St Louis, MO, USA), D-glucose, 
citric acid, sodium citrate, sodium chloride, potassium hydroxide, hydrochloric acid, 
sulphuric acid, silica gel, ethyl acetate, dichloromethane, ethanol, methanol and 
chloroform (Merck, Waderville, RSA), porcine insulin (Intervet SA (PTY) Ltd, Isando, 
South Africa), heparin Novo (Novo Nordisk (Pty) Ltd, Johannesburg, RSA), halothane 
(Fluothane®, AstraZeneca Pharmaceuticals, Johannesburg, RSA). All chemical reagents 
were of analytical grade. 
2.3. Plant material 
Syzygium cordatum (Hochst.) [Myrtaceae] was identified and authenticated by Professor 
H. Baijnath, the former Chief Taxonomist/Curator of the University of KwaZulu-Natal's 
Department of Botany. A voucher specimen (collector number MH/05) of the plant has 
been deposited in the University's Botany Discipline Herbarium. Fresh leaves of S. 
cordatum were collected in and around Durban, South Africa, between February and 
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June, 2006 to eliminate seasonal variations of chemical constituents. The leaves were air 
dried at room temperature (±24°C) for approximately four weeks. 
2.4. Bioassay-directed isolation of OA 
Air-dried leaves of S. cordatum (1.65 kg) were milled using a Waring commercial 
blender. The powder was extracted thrice at room temperature for 24 h intervals 
sequentially in hexane, dichlomethane, ethyl acetate and methanol on each occasion with 
3 litres, to give residues of hexane-solubles (HES), dichloromethane-solubles (DCMS), 
ethyl acetate-solubles (EAS), and methanol-solubles (MES), respectively. Filtering was 
done using 30 cm filter papers (Whatman, England). The filtrates were concentrated in 
vacuo at 60±1°C using a laboratory 4000 efficient rotary evaporator (supplied by 
Laboratory Consumables and Chemical Supplies, South Africa). 
2.4.1. Thin layer chromatography 
The crude extracts were analyzed by thin layer chromatography (TLC) on pre-coated 
aluminium plates using Merck Si gel F254 to reveal the type of chemical constituents 
they contained. This was done by spotting a diluted portion of the crude extract on a TLC 
plate with authentic oleanolic acid. The TLC plate was developed with ethyl 
acetate/hexane (8:2) in a TLC tank. The developed TLC plate was visualised initially by 
exposure to ultraviolet light at 254 to 366 nm wavelength and then sprayed with 
anisaldehyde/ sulphuric acid/ alcohol solution and heated at 110°C. Appearance of a blue 
or violet-blue colouration indicated the presence of triterpenoids (Hostettmann and 
Marston, 1995). 
2.4.2. Isolation of OA 
Since preliminary studies indicated that the EAS of S. cordatum contained triterpenoids, 
the solubles were, therefore, subjected to further purification processes. A portion of EAS 
(2 g) was fractionated on silica gel (70-230 mesh, 3.5 x 45 cm) by open column 
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chromatography using a step gradient of n-hexane-ethyl acetate 90:10 (250 ml), 80:20 
(250 ml), and 70:30 (800 ml). Data from collected fractions analyzed by TLC were 
compared with authentic OA values. Fractions were pooled according to similar TLC 
profiles and concentrated in vacuo using a rotary evaporator at 55°C. The concentrates 
were reconstituted using minimal amounts of chloroform and allowed to air dry in pre-
weighed vials. Measured eluates were collected and combined into fractions on the basis 
of their thin layer chromatography (TLC) similarities. The eluates with similar TLC 
profiles to oleanolic acid were combined and subjected to further chromatographic 
purification. 
2.4.3. OA structure elucidation 
Pure OA was obtained by recrystallization with ethanol and its structure (Figure 4) 
confirmed by spectroscopic analysis using ID and 2D, 'H and 13C Nuclear Magnetic 
Resonance (NMR) techniques. 
2.5. Animals 
Male Sprague Dawley rats (250-300 g) bred and housed in the Biomedical Resource Unit 
of the University of KwaZulu-Natal, Westville campus were used in the study. The 
animals were maintained under standard laboratory conditions of constant temperature 
(22±2 °C), CO2 content of <5000 p.p.m, relative humidity of 55±5%, and illumination 
(12 h light/dark cycles) and the noise levels of <65 decibels. The animals had free access 
to standard rat chow (Meadows, Pietermaritzburg, South Africa) and water. 
2.5.1. Induction of diabetes mellitus 
Diabetes mellitus was induced in male Sprague Dawley rats with a single intraperitoneal 
injection of streptozotocin (STZ), at a dosage of 60 mg/kg dissolved in freshly prepared 
0.1M citrate buffer (pH 6.3). Control animals were injected with the vehicle. Animals 
that exhibited glucosuria after 24 h, tested by urine strips (Rapidmed Diagnostics, 
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Sandton, South Africa) were considered diabetic. Blood glucose concentration of 20 
mmol/1 or above measured after one week was considered as a stable diabetic state before 
experimental procedures. 
2.6. Experimental design 
Oral glucose tolerance test (OGTT) responses were carried out in conscious non-diabetic 
and STZ-induced diabetic rats. The effects of short-(acute) administration of OA on renal 
fluid and electrolyte handling were evaluated in anesthetized non-diabetic and STZ-
induced diabetic rats while the long-term (subchronic) effects of OA on renal parameters 
and blood glucose were assessed in conscious animals. 
2.7. Acute studies 
2.7.1. OGTT protocol 
OGTT responses were carried out as previously described (Musabayane, Gondwe, 
Kamadyaapa, Chuturgoon and Ojewole, 2007) with slight modifications. The rats were 
divided into the following groups: non-diabetic control, non-diabetic treated, STZ-
induced diabetic rats control and STZ-induced diabetic treated rats (n=6 in each group). 
An 18 h fast was allowed for all animals, followed by measuring blood glucose (time 0) 
and then loading glucose (0.86 g/kg, body weight, p.o.). OGTT responses were also 
monitored in separate groups of non-diabetic and STZ-induced diabetic rats OA was 
administered at various doses (40, 80 and 120 mg/kg, p.o.). OA was freshly dissolved in 
dimethyl sulphoxide (DMSO, 2 ml) and normal saline (19 ml) before use in each case 
(Musabayane, Mahlalela, Shode and Ojewole, 2005). Rats treated with deionized water 
(3 ml/kg, p. o.) served as control animals. 
Separate groups of non-diabetic and STZ-induced diabetic rats administered insulin (200 
ug/kg, s.c.) (Intervet, SA Pty Ltd, Isando, South Africa), metformin (1,1-
dimethylbiguanide hydrochloride) (500 mg/kg, p.o.) (Sigma Aldrich, St. Louis, Missouri, 
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USA, or glibenclamide (glyburide; Af-p-[2-(5-chloro-2-methoxybenzamido) 
ethylbenzene-sulfonyl-JV'-cyclohexylurea] (500 ug/kg, p.o) (Sigma Aldrich, St. Louis, 
Missouri, USA), acted as positive control animals. This was to establish whether OA 
possesses hypoglycaemic effects comparable to standard anti-diabetic drugs. 
The influence of standard drugs on OA-induced OGTT responses was studied in separate 
groups of animals that were similarly treated with OA at either 40 or 80 mg/kg followed 
by insulin (100 or 200 ug/kg, s.c), metformin, (250 or 500 mg/kg, p.o.) and 
glibenclamide (250 or 500 mg/kg, p.o.). Blood samples were collected from the tail veins 
of the animals at 15 min intervals for the first hour, and hourly thereafter for the 
subsequent 3 h for glucose measurements, using Bayer's Glucometer Elite® (Elite (Pty) 
Ltd, Health Care Division, Isando, South Africa). 
2.7.1.1. Effects of acute OA treatment on insulin secretion 
Plasma insulin concentrations were determined in blood samples of separate groups of 
non-diabetic and STZ-induced diabetic rats (n=6 in each group) following separate 
administration of OA (80 mg/kg, p.o.), metformin (500 mg/kg, p.o.), insulin (200 (xg/kg, 
s.c.) or OA combined with the standard anti-diabetic drugs for plasma insulin 
measurement. This allowed comparison of incremental changes in plasma insulin 
concentration following OA administration with levels observed in control rats and 
animals treated with insulin. In preliminary experiments, the plasma lowering effect was 
found to reach plateau within 30 min and maintained for 60 min in fasted rats after OA or 
insulin administration. Thus, plasma insulin concentration was determined using blood 
samples collected after 60 min. 
The rats were anaesthetized in an anaesthetic chamber with halothane (Fluorothane®, 
Astra Zeneca pharmaceuticals (Pty) LTD) and blood was collected by cardiac puncture 
into pre-cooled heparinized tubes for insulin determination. The blood was centrifuged 
(Eppendorf centrifuge 5403, Germany) at 4 °C, 3000rpm for 15 minutes and separated 
plasma was stored at -70 °C in a Bio Ultra freezer (Snijers Scientific, Holland) until 
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insulin assay. 
2.7.2. Acute effects of OA on renal function 
Acute effects of OA on renal function and electrolyte handling were assessed in separate 
groups of anaesthetized non-diabetic and STZ-induced diabetic rats (n=6 in each group) 
using a modified procedure that has been previously described (Musabayane, Gondwe, 
Kamadyaapa, Chuturgoon and Ojewole, 2007) (see Figure 2 page 38). The animals were 
anaesthetized by an intraperitoneal injection of inactin (5-ethyl-5-(l'-methylpropyl)-2-
thiobarbiturate, Sigma-Aldrich, St Louis, MO, USA) at 0.11 g/kg body weight. 
Tracheostomy was performed to maintain clear airway. The right jugular vein was 
cannulated with polyethylene tubing (internal diameter, (i.d.) 0.86 mm; external diameter, 
o.d. 1.27 mm; Portex, Hythe, Kent, UK) to allow intravenous infusion of 0.077M NaCl at 
9 ml/h using Harvard Apparatus Syringe Infusion Pump 22 (Harvard Apparatus, 
Holliston, Massachusetts, USA). The urinary bladder of each rat was exposed after an 
abdominal incision and cannulated with similar calibre polythene tubing to facilitate 
timed collection of urine samples. The body temperature of each animal was maintained 
at 37±1 °C with a heated table. Non-diabetic and STZ-induced diabetic control groups 
were placed on a continuous infusion of 0.077M NaCl at 9 ml/h. Following an initial 
equilibration period of 3'/2 h, eight consecutive urine collections were made into pre-
weighed plastic vials at 30 min intervals over the subsequent 4 h for measurements of 
urine flow, and Na+, CF and K+ excretion rates. The control group was designed to check 
the stability of renal function. 
In those animals in which the effects of OA were studied, OA was added to the infusate 
at 90 ng/ h for 1 Vi h (treatment period), resulting in a total dose of 0.45 mg/ kg (for a 300 
g rat), before the animals were returned to infusate alone for the last 1/4 h (recovery 
period). Depth of anaesthesia was monitored throughout the experiments, and additional 
i.v. bolus doses of inactin (0.05 g/kg body weight) were administered when necessary. 
35 
2.7.2.1. Acute effects of OA on blood pressure 
The acute effects of OA on mean arterial blood pressure (MAP) were assessed in parallel 
groups of rats (n=6 in each group) prepared as for renal studies, except that a heparinized 
cannula (Portex i.d. 0.86 mm; o.d. 1.27 mm, Hythe, Kent, UK) was inserted into the left 
common carotid artery and attached to a blood pressure transducer (Stratham MLT 
0380/D, AD Instruments Inc., Bella Vista, NSW, Australia) compatible with the 
PowerLab System ML410/W, (AD Instruments Inc., Bella Vista, NSW, Australia) (see 
Figure 2). This permitted recording of mean arterial blood pressure at 30 minute intervals 
following equilibration for the subsequent 4 h experimental period. 
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Figure 2: Layout of the Harvard Apparatus infusion pump and Power lab transducer 
systems used for investigations of acute effects of OA on renal function and mean arterial 
blood pressure. 
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2.8. Short-term studies 
2.8.1. Physico-metabolic changes 
Groups of treated and control non-diabetic and STZ-induced diabetic male Sprague-
Dawley rats (250-300g body weight) were housed individually in Makrolon 
polycarbonate metabolic cages (Techniplats, Labotec, South Africa) for five weeks at the 
Biomedical Resource Unit, University of KwaZulu Natal, (n=6 in each group). The 
animals were maintained on a 12 h dark/light cycle with free access to water and standard 
rat chow (Meadows, Pietermaritzburg, South Africa). Effects of OA were investigated in 
rats orally administered OA (80 mg/kg) twice every third day at 09h00 and 15h00 by 
means of a bulbed steel tube for 5 weeks. Rats similarly treated with deionized water (3 
ml/kg, p.o.) and standard anti-diabetic drugs (metformin, 500 mg/kg, p.o., insulin, 200 
(j.g/kg, s.c) acted as untreated and treated positive controls, respectively. The 
hypoglycaemic effects of the administration of OA (80 mg/kg, p.o.) followed by insulin 
(200 |ig/ kg, s.c.) were also monitored in separate groups of animals. 
24 h urine volume and urinary outputs of glucose, Na+, K+ and CI" were determined for 
all groups every third day. The amounts of food and water consumed were recorded daily 
at 09h00. The weights of the animals were assessed every third day at 09h00. 
2.8.2. Short-term effects of OA on MAP 
Mean arterial blood pressure (MAP) was monitored once every week at 09h00 in 
conscious Sprague Dawley rats for five weeks using the non invasive tail cuff method 
(IITC Model 31 Computerised Blood Pressure Monitor, Life Sciences, Woodland Hills, 
CA) as previously described (Musabayane, Gondwe, Kamadyaapa, Chuturgoon and 
Ojewole, 2007). The unit utilizes IITC hardware system employing an automatic scanner 
pump, sensing cuff and amplifier to measure blood pressure in the animals' tail and the 
results are displayed on the computer screen (see Figure 3). The equipment was 
calibrated before each day of mean arterial blood pressure measurements. The animals 
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were warmed in an enclosed chamber (IITC Model 303sc Animal Test Chamber, IITC 
Life Sciences, Woodland Hills, California, USA) for 30 minutes at ±30°C before taking 
three blood pressure recordings of each animal (Gondwe, Kamadyaapa, Tufts, 
Chuturgoon, Ojewole and Musabayane, 2008). 
39 

Figure 3: Layout of the IITC Model 303sc Animal Test Chamber apparatus used for 
investigations of short-term measurement of mean arterial blood pressure in non-diabetic 
and STZ-induced diabetic rats. 
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2.8.3. Terminal studies 
Blood samples were collected by cardiac puncture 24 h after the last treatment from all 
non fasted groups of animals for glucose, electrolytes, urea, creatinine, osmolality and 
insulin assay at the end of the 5-week treatment period. The animals were initially 
anaesthetized by placing them in an anaesthetic chamber with 100 mg/kg of halothane 
(Fluorothane®, Astra Zeneca 2002) pharmaceuticals (Pty) LTD) for 3 minutes. Blood 
was centrifuged in an Eppendorf centrifuge 5403, Germany for 15 minutes at 3500 rpm g 
x 100 at 4 °C to separate the plasma. Separated plasma samples for insulin measurements 
were stored in a Bio Ultra freezer (Snijers Scientific, Holland) at -70 °C until assayed. 
Kidneys were removed, weighed and snap frozen in liquid nitrogen. The liver and 
gastrocnemius muscles were removed and weighed gravimetrically (Mettler balance PC 
180-insruments, Protea Laboratory Services, South Africa) and then for glycogen 
measurement placed immediately on ice (Ong and Khoo, 2000). The plasma, liver and 
muscle samples were stored in a BioUltra freezer (Snijers Scientific, Holland) at -70 °C 
until assayed. 
2.9. Laboratory analyses 
2.9.1. Biochemical measurements 
Urine volume was determined gravimetrically using a balance (Mettler balance PC 180-
instruments, Protea Laboratory Services, South Africa). Na+, K+, CI", urea and creatinine 
concentrations were determined by ion activity using the Beckman Coulter (Synchron 
LX20 Clinical Systems, USA). Creatinine estimation employed the reaction of creatinine 
and sodium picrate to form creatinine picrate. Urea estimation employed the hydrolytic 
degradation of urea in the presence of urease. The methods used reagent kits from 
Beckman Coulter, Dublin, Ireland. Osmolalities of the plasma and urine were measured 
on 50 ul samples by freezing point depression using an osmometer (Osmomat 030, Lasec 
Laboratory and Scientific Company, Berlin, Germany). Glomerular filtration rate (GFR), 
as assessed by creatinine clearance (Co) was calculated using the standard formulae from 
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measurements of the plasma and urinary concentrations of creatinine and urine flow rate 
in the 5 th week. 
2.9.2. Insulin assay 
Plasma insulin was measured using ultra sensitive rat insulin ELISA kit (DRG 
diagnostics EIA-2746 GmbH, Marburg, Germany). The kit contained a 96 well plate 
coated with mouse monoclonal anti-insulin, standards, enzyme conjugate, enzyme 
conjugate buffer, wash buffer, substrate 3,3',5,5'-tetramethylbenzidine (TMB) and a stop 
solution. The principle of the assay is a solid phase two-site enzyme immunoassay based 
on the direct sandwich technique in which two monoclonal antibodies are directed 
towards separate antigenic determinants on the insulin molecule. During the incubation 
period insulin in the sample reacts with peroxidase-conjugated anti-insulin antibodies and 
anti-insulin antibodies bound to the microtitration well. The washing step removes 
unbound enzyme labeled antibody, leaving the bound conjugate which reacts with TMB. 
This reaction is stopped by adding acid to give a colorimetric endpoint that is read 
spectrophotometrically. 
Each determination was performed in duplicate for standards and samples. The insulin 
assay procedure was as follows: 50 u.1 of each insulin standard (0.02, 0.05, 0.15, 0.4 and 1 
(j.g/1) were added to anti-insulin wells. 50 u.1 of the plasma samples were then added to 
the remaining wells followed by 50 \i\ enzyme conjugate to all wells of standards and 
plasma samples. The plates were incubated at room temperature for 2 hours on a plate 
shaker (Velp® Scintifica, Milano, Italy) followed by aspirating the reaction volume, 
adding wash buffer (350 ul) and aspirating 6 times. After the final wash the plates were 
inverted firmly against absorbent paper to absorb all the liquid in the plates. 200 (xl 
substrate TMB was added to all the wells and incubated for 30 minutes. The reaction was 
stopped by adding 50 ul of stop solution to all wells and mixing on a shaker for 5 
minutes. The absorbance was measured at 450 nm using a Biotek microplate reader 
(Winooski, Vermont, USA). A standard curve was constructed from the absorbance 
values of the known concentrations of the standards using the spline regression curve in 
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Graph Pad Instat software (version 4.00). The respective insulin concentrations of the 
unknown samples were then extrapolated from the standard curve. The lower and upper 
limits of detection were 1.39 pmol/1 and 960 pmol/1, respectively. The intra-assay 
analytical coefficient of variation ranged from 4.4 to 5.5% and the inter-assay coefficient 
variation from 4.7 to 8.9%. 
2.9.3. Glycogen measurements 
Hepatic and muscle glycogen concentrations were determined as described by Ong and 
Khoo, (2000). Briefly, the tissue samples were homogenized in 2 ml of 30% potassium 
hydroxide (300 g/1) and boiled at 100 °C for 30 min, and then cooled in ice saturated 
sodium sulphate. 
2 u.1 of each sample were added to 2 ul of 95% ethanol mixed with 1.2 ml of distilled 
water. Blanks were made by adding 2 u,l of distilled water followed by ethanol mixed 
with 1.2 ml of distilled water. 4 ml of anthrone reagent (0.5 g of anthrone powder was 
dissolved in 250 ml of sulphuric acid (H2SO4) to make the reagent) was pipetted into 
samples and blanks. Glycogen powder from oyster, type II was used to prepare standards 
(10-2000 mg/1). The samples together with the blanks were boiled for 10 minutes after 
vortexing. The glycogen was precipitated with ethanol, pelleted and resolubilized in 
deionized water. The glycogen content determined by treatment with anthrone reagent 
was measured at 620 nm using the Cary dual spectrophotometer (Biochrom Ltd, 
Cambridge, England) using Cary Win UV Simple Reads Application, software version 
3.00(182). 
3.0. Data presentation 
All data were expressed as means ± standard error of means (SEM). Data for untreated 
non-diabetic and STZ-induced diabetic rats were used as baseline. The data were treated 
and presented separately for the non-diabetic and STZ-diabetic rats. OGTT responses to 
oleanolic acid alone and/or standard anti-diabetic drugs were presented separately for the 
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non-diabetic and STZ-induced diabetic rats. This was to establish whether OA possesses 
pharmacological activities comparable to standard antidiabetic drugs already in use or 
influenced standard drugs' evoked OGTT responses. Renal excretion data for acute 
studies were presented graphically showing 30-minute collections over the 4-h post-
equilibration period. The total amounts of fluid voided and electrolytes excreted during 
the VA h administration of the OA were calculated and compared to values in controls for 
the corresponding time. For chronic studies, calculating mean daily fluid voided and 
urinary amounts of electrolytes excreted assessed renal function. GFR was evaluated by 
creatinine clearance as assessed by 24-hour urinary excretion rates of creatinine in 
relation to plasma concentration. Statistical analyses were done with GraphPad InStat 
Software (version 4.00, GraphPad Software, San Diego, California, USA). Statistical 
comparison between groups was done using one way one-way analysis of variance 
(ANOVA) followed by Turkey-Kramer multiple comparison test. Values of p <0.05 were 




This chapter describes the following: 
i) phytochemical and spectroscopic data elucidating the structure of OA; 
ii) OGTT responses and acute and sub-chronic renal effects of various treatments and. 
iii) sub-chronic effects on body weight, food and water intake 
3.1. Structural elucidation of OA 
The S. cordatum crude leaf extract was sequentially extracted with ethyl acetate to give ethyl 
acetate-solubles (EAS). The percentage yield of OA from EAS varied from 0.79% to 1.72%. 
Spectroscopic analyses of the white powder obtained after recrystallization with ethanol carried 
out using ]H- and 13C-NMR (ID and 2D) spectroscopy are shown in Figure 4. Figure 4A is the ID 
*H NMR spectra showing all the hydrogens in the molecule. Figure 4B shows the ID 13C NMR 
spectra of all carbons in the molecule with two carbon signals at 143.6 and 122.7 ppm 
corresponding to the carbon-carbon double bond at carbon 12 and 13. Figure 4C and 4D are the 
two dimensional 'H and 13C NMR spectra of OA. In Figure 4C the bottom line shows all the 
carbons attached to hydrogen atoms; the middle line shows carbons that are attached to one 
hydrogen atom (CH groups) and in the uppermost line, signals pointing downwards are CH2 and 
upwards are CH and CH3. Table 1 compares the relative resonation frequencies of all the carbon 
atoms in the S. cordatum-derived OA with literature data (Mahato and Kundu 1994). Figure 5 
shows OA structure as elucidated by *H- and 13C-NMR. 
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Figure 4: Syzygium cordatum leaf derived OA one dimensional 'H and 13C- NMR spectra (A-B) and two dimensional 'H and 
13C- NMR spectra by Distortion Enhancement Proton Testing (DEPT) (C) and Heteronuclear multiple quantum coherence 
(HMQC) (D). 
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Table 1: 13C (100.64 MHz) Bruker Avance III NMR spectral data of plant derived OA and 
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Figure 5: Structure (A) and numbering (B) of oleanolic acid (International Union of Pure and 
Applied Chemistry, IUPAC). 
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3.2. OGTT responses 
Oral glucose tolerance (OGTT) responses to various doses of OA (40, 80 and 120 mg/kg) were 
monitored in separate groups of non-diabetic and STZ-induced diabetic rats following a glucose 
load (0.86 g/kg, p.o.) after 18-h fast. Rats treated with deionized water or standard anti-diabetic 
drugs (insulin, metformin and glibenclamide) acted as untreated and treated positive controls, 
respectively. 
3.2.1. OGTT responses to standard anti-diabetic drugs 
Figure 6 compares OGTT responses of separate groups of non-diabetic and STZ-induced diabetic 
rats to anti-diabetic drugs with respective control animals. 
3.2.1.1. Non-diabetic rats 
The blood glucose concentrations of control non-diabetic animals increased to peak levels (7 
mmol/1) by 15 minutes following glucose load from preloading values of 4.2±0.1 mmol/1, but 
declined at the end of the 4 h experimental period to values slightly higher than the preloading 
values (5.0±0.1 mmol/1), though not statistically significant (Figure 6). All standard anti-diabetic 
drugs significantly (p<0.05) reduced blood glucose concentrations at all sampling time points by 
comparison with the control groups. The blood glucose lowering effects of insulin were most 
potent throughout the 4-h experimental period when compared with the effects of metformin and 
glibenclamide. Blood glucose concentrations of standard drug-treated animals, however, returned 
to pre-loading values at the end of the experiment. 
3.2.1.2. STZ-induced diabetic rats 
The mean fasting blood glucose concentration of STZ-induced diabetic rats was five-fold more 
than that of non-diabetic animals (Figure 6). Blood glucose concentrations of control STZ-induced 
diabetic rats increased to a peak value of 24.8±0.5 mmol/1 after 15 minutes of glucose loading and 
declined to values below the pre-loading values by the end of the 4-h experimental period (Figure 
6). OGTT responses of separate groups of STZ-induced diabetic rats to insulin and metformin 
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were lower at all the time points that blood was sampled when compared with control groups at the 
corresponding time periods. Glibenclamide, however, did not have any effects on blood glucose of 
these STZ-induced diabetic rats. 
3.2.2. OGTT responses to OA 
OGTT responses to various doses of OA (40, 80 and 120 mg/kg, p.o.) were monitored in non-
diabetic and STZ-induced diabetic rats to determine the blood glucose lowering effects of the 
triterpene. 
3.2.2.1. Non-diabetic rats 
Figure 7 shows that OA decreased blood glucose concentrations of non-diabetic rats throughout 
the experimental period by comparison with control animals. The OGTT responses were, however, 
not dose-dependant although the highest dose (120 mg/kg) showed the most potent effects. The 
blood glucose concentrations of OA-treated non-diabetic rats returned to pre-loading values at the 
end of the 4-h experimental period. 
The influence of standard drugs (insulin, metformin, and glibenclamide) on OA-induced OGTT 
responses was studied in separate groups of animals that were similarly treated with the OA 
followed by the standard drugs. OGTT responses to combined treatments were, however, not 
significantly different to responses evoked by each respective drug alone (Figures 8 and 9). 
3.2.2.2. STZ-induced diabetic rats 
Figure 7 compares OGTT responses to various doses of OA of STZ-induced diabetic rats with 
control diabetic animals. All doses of OA significantly decreased blood glucose concentrations 
after 30 minutes with the highest dose showing most potent effects. The blood glucose 
concentrations were significantly low throughout the 4 h experimental period by comparison with 
control animals at corresponding times. Administration of OA in combination with standard anti-
diabetic drugs (metformin, glibenclamide and insulin) reduced blood glucose of STZ-induced 
diabetic rats (Figures 8 and 9). The blood glucose concentrations, however, decreased to 
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hypoglycaemic levels (2.5±0.2 mmol/1, n=6 in each group) in animals treated with OA (80 mg/kg) 
followed by insulin (200 ug/kg) at the end of the experiment (Figure 9 A). 
3.2.3. OA effects on insulin secretion 
Plasma concentrations of insulin and glucose were monitored in separate groups of non-diabetic 
and STZ-induced treated with OA and/or standard hypoglycaemic drugs 60 min after a glucose 
load to assess the influence of OA on pancreatic insulin secretion. 
3.2.3.1. Non-diabetic rats 
Separate treatments with insulin alone or in combination with OA significantly increased plasma 
insulin concentrations in non-diabetic rats with concomitant reduction of blood glucose (Figure 
10). Metformin and OA, however, reduced blood glucose without altering plasma insulin 
concentrations (Figure 10). 
3.2.3.2. STZ-induced diabetic rats 
The plasma insulin concentrations of STZ-induced diabetic rats were significantly low by 
comparison with levels of non-diabetic rats (Figure 10). The plasma insulin concentrations were 
not altered by any other treatment in STZ-induced diabetic rats except for animals administered 
insulin alone or in combination with OA. Blood glucose concentrations were reduced by all 
treatments. 
In summary OA, like standard drugs, decreased blood glucose concentrations in both non-diabetic 
and STZ-induced diabetic rats without altering insulin secretion. The hypoglycaemic effects were 
most significant in STZ-induced rats administered OA combined with insulin by comparison with 
all other treatments. OA alone did not alter insulin secretion of non-diabetic rats. 
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Figure 6: Comparison of OGTT responses to standard anti-diabetic drugs in separate groups of 
non-diabetic rats (A) and STZ-induced diabetic (B) rats with respective control animals. Values 
are presented as means, and vertical bars indicate SEM (n=6 in each group). 
* p<0.05 by comparison with respective control animals 
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Figure 7: Comparison of OGTT responses to various 0A doses in separate groups of non-diabetic 
rats (A) and STZ-induced diabetic (B) rats with respective control animals. Values are presented as 
means, and vertical bars indicate SEM (n=6 in each group). 
* p<0.05 by comparison with respective control animals 
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Figure 8: Comparison of OGTT responses to OA (40 mg/kg) alone and in combination with 
standard anti-diabetic drugs in separate groups of non-diabetic rats (A) and STZ-induced diabetic 
(B) rats with respective control animals. Values are presented as means, and vertical bars indicate 
SEM (n=6 in each group). * p<0.05 by comparison with respective control animals 
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Figure 9: Comparison of OGTT responses to OA (80 mg/kg,) alone and in combination with 
various standard anti-diabetic drugs in separate groups of non-diabetic rats (A) and STZ-induced 
diabetic (B) rats with respective control animals. Values are presented as means, and vertical bars 
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Figure 10: Comparison of the effects of OA and standard anti-diabetic drugs on plasma insulin 
and glucose concentrations in non-diabetic and STZ-induced diabetic rats with respective control 
groups. Blood samples were collected 60 min after glucose load. Values are presented as means, 
and vertical bars indicate SEM (n=6 in each group). 
* p<0.05 by comparison with respective control animals; 
p<0.05 by comparison with respective non-diabetic animals 
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3.3. Acute renal effects of OA 
Acute effects of OA on kidney function were investigated in anaesthetized non-diabetic and STZ-
induced diabetic rats challenged with hypotonic saline after a 3/4 h equilibration for 4 h of 1 h 
control, 11/2 h treatment and 1 V% h recovery periods. 
3.3.1. Non-diabetic rats 
Figure 11 shows stable urine flow and Na+, K+ and CI" excretion rates of control non-diabetic rats 
during the 4 h post equilibration period. Acute intravenous infusion of OA during the V/2 h 
treatment period increased Na+ excretion rate from a pre-treatment mean value of 718±25 umol/h 
to 880±25 umol/h (n=6 in each group) without affecting K+, CI" and urine flow rates (Figure 11). 
The increase in urinary Na+ output was reflected as the increased mean total amount of Na+ 
excreted during the treatment period (Table 2). 
3.3.2. STZ-induced diabetic rats 
The mean urine flow, Na+, K+ and CI" excretion rates of anaesthetized, control and OA-treated STZ-
induced diabetic rats during the 4 h post-equilibration period are compared in Figure 12. STZ-induced 
diabetic control rats exhibited lower urine flow and electrolyte excretion rates by comparison with 
non-diabetic rats. OA infusion increased the mean Na+ excretion rate from a pre-treatment value of 
297±29 umol/h to 420±38 umol/h by the cessation of 1V2 h treatment. The increase in Na+ excretion 
was maintained during the recovery period. OA, however, did not influence K+, CI" and urine 
excretion rates by comparison with control animals (see Figure 12). The mean total amounts of Na+ 
excreted during the 11/2 h OA treatment was significantly more than that of control animals at the 
corresponding time. The total amounts of fluid voided and K+ and CI" excreted were, however, not 
altered by OA treatment. 
In summary acute OA treatment increased Na+ excretion in non-diabetic and STZ-induced diabetic 
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Figure 11: Comparison of the effects of 1!4 h OA infusion on Na+ (A), K+ (B) and Cf (C) 
excretion and urine flow (D) rates with control animals in anaesthetized non-diabetic rats (n=6 in 
each group). Values are presented as means, and vertical bars indicate SEM (n=6 in each group). 
* p<0.05 by comparison with control animals at each corresponding time 
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Figure 12: Comparison of the effects of IV2 h OA infusion with control animals on Na+ (A), K+ 
(B) and Cl" (C) excretion and urine flow (D) rates in anaesthetized STZ-induced diabetic rats (n=6 
in each group). Values are presented as means, and vertical bars indicate SEM (n=6 in each group). 
* p<0.05 by comparison with control animals at each corresponding time 
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Table 2: Comparison of total mounts of urine volume, Na+, K+ and CI" excreted during the 
treatment period by anaesthetized OA-treated non-diabetic and STZ-induced diabetic rats with 
respective control animals (n = 6 in all groups). Data are expressed as means ± SEM (n = 6 in each 
group). * p<0.05 by comparison with respective control animals; p<0.05 by comparison with 



























3.4. Short-term effects on body weight, food and water intake 
Table 3 compares the effects of OA and/or standard anti-diabetic drugs on mean weight changes, 
food and water intake in separate groups of non-diabetic and STZ-induced diabetic rats over a 5-
week period with respective control animals. Non-diabetic control rats progressively gained weight 
while STZ-induced diabetic rats exhibited severe wasting throughout the 5-week period. OA 
administration reduced the body weight loss of STZ-induced diabetic rats in the 5th week, whereas 
treatment with metformin, insulin or combined insulin and OA stabilized body weight of STZ-
induced diabetic rats from the 3rd to the 5th week. 
The total amounts of food taken per day by control non-diabetic and STZ-induced diabetic rats and 
respective treated groups did not significantly differ, except for metformin which significantly 
decreased food intake of STZ-induced diabetic rats in the 5th week. 
Control STZ-induced diabetic rats exhibited polydipsia by comparison with the respective non-
diabetic animals as evidenced by the fact that STZ-induced diabetic rats drank four to five times 
more water than non-diabetic rats. OA administration caused significant reduction of water intake 
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by STZ-induced diabetic rats in week 5 by comparison with respective control animals at the 
corresponding period. On the other hand, separate treatment of STZ-induced diabetic rats with 
metformin, insulin alone or in combination with OA significantly (p<0.05) reduced water intake 
from the first week up to the end of the five weeks. 
In summary, treatment with OA alone or in combination with insulin stabilized body weight of 
STZ-induced diabetic rats without altering food intake. 
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Table 3: Comparison of the effects of 5-week treatment with OA and/or standard anti-diabetic 
drugs of non-diabetic (ND) and STZ-induced diabetic animals on food intake, water intake and 
body weight changes with the respective control animals (n=6 in each group). Values are presented 






































































26 4 1 
34 4 2 
28 4 1 
33 4 2 
28 4 1 
2 7 4 1 * 
26 4 1 
36 4 1 
30 4 1 

























































































































23 4 2 
-5 4 2 
24 4 1 
- 1 4 3* 
24 4 1 
1 4 2* 
27 4 1* 
- 1 4 2* 
2541 
2 4 2* 
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3.5. Short-term renal effects of OA 
The effects of OA on renal function were studied in individually-caged non-diabetic and STZ-
induced diabetic rats that were treated with OA (80 mg/kg, p.o.) twice every third day for five 
weeks. 
3.5.1. Non-diabetic rats 
The mean daily Na+ excretion rate of control non-diabetic rats ranged from 547±21 mmol/day to 
678±68 mmol/day throughout the 5 week experimental period (Figure 13). OA administration 
significantly increased the mean daily Na+ output from 1st week value of 645±28 mmol/day to 
837±49 mmol/day by the end of the 5th week, but the volume of urine voided and urinary outputs 
of K+ and CT were not altered. The OA-elicited natriuresis was not reflected in plasma collected 
after 5 weeks treatment as the plasma Na+ concentrations compared with those of control animals 
at the corresponding time (Table 4). OA administration for 5 weeks significantly reduced plasma 
creatinine concentrations of non-diabetic rats with concomitant elevation of GFR. In contrast, 
plasma urea concentrations of non-diabetic animals were not altered by OA treatment. OA 
administration caused slight, but statistically insignificant decreases of plasma and increases of 
urine osmolalities of non-diabetic rats (Table 4). Administration of OA did not affect kidney 
masses of non-diabetic rats (Table 4). 
3.5.2. STZ-induced diabetic rats 
The mean daily urine volume of untreated STZ-induced diabetic rats was greatly elevated throughout 
the 5-week compared to non-diabetic control animals, although the urinary Na+, K+ and CI" outputs 
were enormously reduced (Figure 14). Administration of OA increased urinary Na+ outputs of STZ-
induced diabetic rats from 35±3 mmol/day in the first week to 48±2 mmol/day in the 5th week. The 
mean daily urine volume, urinary K+ and CI" outputs were, however, not altered by OA 
administration. 
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As described for non-diabetic rats, Table 4 shows that OA administration in STZ-induced diabetic 
rats did not affect plasma Na+, K+ and CI" by the end of the 5-week experimental period. In 
contrast with non-diabetic rats, OA administration significantly reduced (p<0.05) plasma 
osmolality of STZ-treated diabetic rats with concomitant increase in urine osmolality. Plasma 
creatinine and urea concentrations of STZ-induced diabetic rats were elevated when compared 
with non-diabetic rats. OA treatment did not alter plasma urea concentrations unlike plasma 
creatinine levels which were significantly reduced with a concomitant elevation of GFR (Table 4). 
Kidney mass which was significantly increased in STZ-induced diabetic rats by comparison with 
non-diabetic animals was not altered by sub-chronic OA treatment (Table 4). 
3.5.3. Haemodynamic changes 
Acute infusion of hypotonic saline to control non-diabetic rats did not cause any significant 
variations in the mean arterial blood pressure (MAP) throughout the 4-h post-equilibration period 
(Figure 15). Acute intravenous infusion of OA at 90 ug/h for 1 Vz h, however, reduced the mean 
arterial blood pressure from a pre-treatment value of 115±1 mmHg (n=6) to 105±1 mmHg (n=6) by 
the end of 1 !4 h treatment period. The hypotensive effect of OA persisted during the post-treatment 
period to a mean value of 108±2 mmHg at the end of the experiment (Figure 15A). Similar trends 
were observed in STZ-induced diabetic rats. The MAP changes due to long-term (sub-chronic) OA 
treatments are shown in Figure 15. Treatment of the rats with OA (80 mg/kg daily for 5 weeks, 
p.o.) caused significant decreases (p<0.05) in MAP in non-diabetic and STZ-treated diabetic rats 
throughout the study period by comparison with control rats at the corresponding time periods 
(Figure 15). 
3.5.4. Summary of the sub-chronic effects of OA 
Sub-chronic OA treatment significantly increased Na+ excretion rates of non-diabetic and STZ-
induced diabetic rats without affecting the volumes of urine voided and urinary concentrations of K+ 
and CI". OA treatment decreased plasma concentrations of creatinine with concomitant elevation of 
creatinine clearance Ccr. Significant hypotensive effects of OA were also observed in non-diabetic 
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Time ( w e e k s ) 
Figure 13: Comparison of 24h Na+(A), K+ (B), CI" (C) excretion and urine flow (D) rates in non-
diabetic rats treated with OA twice every third day with control animals. Values are presented as 
means, and vertical bars indicate SEM (n=6 in each group). * p<0.05 by comparison with control 
animals at each corresponding time 
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Figure 14: Comparison of 24h Na+(A), K+ (B), CI" (C) excretion and urine flow (D) rates in STZ-
induced diabetic rats treated with OA twice every third day with control animals. Values are 
presented as means, and vertical bars indicate SEM (n=6 in each group). *p<0.05 by comparison 
with control animals at each corresponding time 
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Table 4: Plasma biochemical parameters of non-diabetic and STZ-diabetic control and rats 
administered OA twice every third consecutive day for 5 weeks (n = 6 in all groups). 
* p<0.05 by comparison with respective control animals 
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Figure 15: Comparison of acute effects of OA infusion on MAP in non-diabetic and STZ-induced 
diabetic rats (A-B) and sub-chronic short-term administration in non-diabetic and diabetic rats (C-
D) with respective control animals (n=6 in each group). Values are presented as means, and 
vertical bars indicate SEM (n=6 in each group). * p<0.05 by comparison with respective control 
animals at each corresponding time 
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3.5.5. Effects of OA on terminal blood glucose and plasma insulin concentrations 
Figure 16 shows the short-term effects of treatment with OA and standard anti-diabetic drugs on 
blood glucose concentrations and plasma insulin concentrations in non-diabetic and STZ-induced 
diabetic rats measured 24 h after the last treatment. Treatment of non-diabetic rats with OA alone 
or standard anti-diabetic drugs reduced blood glucose concentrations by amounts that did not 
achieve statistical significance. Combined OA and insulin treatment, however, significantly 
decreased blood glucose concentrations of non-diabetic animals by comparison with respective 
control animals. The administrations of OA alone and/or standard anti-diabetic drugs significantly 
(p<0.05) reduced blood glucose concentrations of STZ-induced diabetic rats by comparison with 
the respective control animals. Figure 16 shows that the circulating plasma insulin concentrations 
of control STZ-induced rats were significantly low by comparison with non-diabetic animals. OA 
treatment did not alter plasma insulin concentrations of non-diabetic or STZ-induced diabetic rats. 
Significant increases in plasma insulin concentrations were observed only in non-diabetic and 
STZ-induced diabetic rats treated with combined insulin and OA or insulin alone. Figure 17 shows 
that treatment with OA alone significantly (p<0.05) decreased the excretion of glucose of STZ-
induced diabetic rats throughout the 5-week period by comparison with the respective control rats. 
3.5.5.1. Effects of OA on hepatic and muscle glycogen concentrations 
Hepatic and muscle glycogen concentrations were measured in separate groups of non-diabetic 
and STZ-induced diabetic rats after 5 weeks of treatment with OA alone and/or standard anti-
diabetic rats in an effort to establish in part the mechanism(s) of the hypoglycaemic effects of OA. 
All treatments increased hepatic glycogen concentrations of non-diabetic and STZ-induced 
diabetic rats (Table 5) whereas muscle glycogen concentrations were elevated by these treatments 
only in non-diabetic rats. 
In summary, sub-chronic OA treatment like standard anti-diabetic drugs decreased blood glucose 
concentrations in rats without influencing pancreatic insulin secretion. The hypoglycaemic effects 
were most significant in animals co-administered OA and insulin. Muscle glycogen concentrations 
of STZ-induced diabetic rats were increased by combined insulin and OA treatment. 
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Overall summary of the results of this study 
The absolute stereostructure of S. cordatum derived OA was elucidated using ID and 2D 
1 13 
H NMR and C NMR techniques on the basis of chemical and physicochemical evidence. 
OGTT responses elicited by S. cordatum leaf derived OA in non-diabetic and STZ-induced 
diabetic rats were comparable to those of standard anti-diabetic drugs. 
OA augments the insulin-elicited OGTT responses in STZ-induced diabetic rats. 
OA treatment improved renal function of STZ-induced diabetic rats as shown by increased 
urinary Na+ outputs, reduced plasma creatinine with concomitant increase in GFR. 
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Figure 16: Comparison of the sub-chronic effects of OA and standard hypoglycaemic drugs on 
blood glucose (A) and plasma insulin (B) concentrations in non-diabetic and STZ-induced diabetic 
rats with respective control groups. Blood samples were collected 24 h after the last treatment. 
Values are presented as means, and vertical bars indicate SEM (n=6 in each group). 
* p<0.05 by comparison with respective control animals; 




Figure 17: Comparison of mean daily urinary glucose outputs of control STZ-induced diabetic rats 
with STZ-induced diabetic rats treated with OA twice every third day for 5 weeks (n=6 in each 
group). 
* p<0.05 by comparison with respective control animals 
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Table 5: Comparison of the effects of 5-week treatment with OA alone and/or standard anti-
diabetic drugs on hepatic and muscle glycogen concentrations in non-diabetic and STZ-induced 
diabetic rats with respective control groups. Data are expressed as mean ± SEM (n=6 in each 
group). 
* p<0.05 by comparison with respective control group 
Treatment 
Non-diabetic rats 
(n-6 in each group) 
STZ-induced diabetic 
rats 
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30.3 ± 0.6* 
36.0 ±0.7* 


















The aim of the present study was to investigate the effects of S. cordatum leaf-derived 
OA on blood glucose concentrations and renal function of STZ-induced diabetic rats. The 
results suggest that OA not only has the potential to lower blood glucose and blood 
pressure in diabetes, but may also have beneficial effects on kidney function. The 
findings are of considerable importance because they contextualize the hypoglycaemic, 
renal and hypotensive effects of OA in the management of diabetes. This is clinically 
relevant considering the prevalence of microvascular and macrovascular complications in 
diabetic patients (The Diabetes Control and Complications Trial Research Group, 1993; 
Vinicor, 1994). Management of diabetes mellitus with OA may, therefore, be associated 
not only with the regulation of blood glucose, but also the prevention or alleviation of 
these complications. 
4.2. Structural elucidation of OA 
The absolute stereostructure of OA from the crude ethyl acetate extract of S. cordatum 
leaves was established on the basis of chemical and physicochemical evidence. The 
spectra of the plant-derived OA elucidated using H- and C-NMR was compared with 
previously reported data (Mahato and Kundu 1994). The spectral data of OA, particularly 
the presence of the olefenic bond between carbon 12 and 13 which is peculiar to 
triterpenoids, was identical with that of previously reported OA (Mahato and Kundu, 
1994). The identification of OA from S. cordatum leaves confirms previous reports that 
the S. cordatum leaf crude ethyl acetate extract contains triterpenoid mixtures 
(Musabayane, Mahlalela, Shode and Ojewole, 2005). Other investigators have also 
isolated the triterpenes OA and ursolic acid from various medicinal plants following 
74 
sequential extraction with methanol (Jung et ah, 2007; Begum, Zehra and Siddiqui, 
2008). 
4.3. Hypoglycaemic effects 
The experimental evidence presented in this study extends previous observations in our 
laboratories that the S. cordatum crude leaf extract lowers blood glucose of STZ-induced 
diabetic rats (Musabayane, Mahlalela, Shode and Ojewole, 2005) by indicating that the 
antihypeglycaemic effect is elicited by triterpene constituent, OA. 
The fasting blood glucose concentrations of STZ-induced diabetic rats were significantly 
higher by comparison with the non-diabetic animals. The rise in blood glucose 
concentrations in untreated STZ-induced diabetic rats can be attributed to the absence of 
insulin, since streptozotocin induces permanent diabetes mellitus by direct pancreatic B-
cell cytotoxicity (Junod, Lambert, Stauffacher and Renold, 1969; Pinent, Blay, Blade, 
Salvado, Arola and Arde, 2004). Streptozotocin first isolated from Streptomyces 
achromogenes is an antibiotic that selectively destroys pancreatic B-cells thereby 
inducing type 1 diabetes mellitus (Ruiz, Alegria, Barbera, Farre and Lagarda, 1994; 
Coskun, Kanter, Korkmaz and Oter, 2005; Li et al., 2007; Srinivasan and Ramarao, 
2007). Indeed, plasma insulin concentrations were significantly lower in STZ-induced 
diabetic rats compared with non-diabetic rats, thereby contributing to high glucose 
concentrations. This is consistent with the mechanism of action of streptozotocin on the 
beta-cells of the pancreas (Junod, Lambert, Stauffacher and Renold, 1969; Pinent, Blay, 
Blade, Salvado, Arola and Arde, 2004). The hypothesis is further supported by the 
observation of a steady, gradual fall in blood glucose concentrations of control non-
diabetic rats following glucose load, presumably due to increased pancreatic insulin 
secretion. In addition, glibenclamide was associated with blood glucose reduction only in 
non-diabetic rats and not STZ-induced animals. The hypoglycaemic effect of 
glibenclamide is seen only when pancreatic beta-cell activity is present, as glibenclamide 
action involves augmentation of insulin secretion (Luzi and Pozza, 1997). The blood 
glucose-lowering effects of OA at all doses (40, 80 and 120 mg/kg) in non-diabetic rats 
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could not be separated at any time. OGTT responses of STZ-induced diabetic rats to OA 
at 40 and 80 mg/kg were similar but, significantly lower than those of OA at 120 mg/kg 
throughout (Figure 7). The reasons for the discrepancy of OGTT responses to three doses 
of OA in non-diabetic and STZ-induced diabetic rats remain to be determined. We 
suggest that endogenous insulin masked the differences in hypoglycaemic effects evoked 
by the small range of OA used in non-diabetic rats. 
OA alone and/or insulin and metformin decreased plasma glucose concentrations in non-
diabetic and STZ-diabetic rats following sub-chronic treatment for 5 weeks. Blood 
glucose concentrations of STZ-induced diabetic rats following long-term treatment were 
significantly reduced by all treatments to levels that did not achieve euglycaemia. The 
reduction of blood glucose concentrations of non-diabetic rats did not reach statistical 
significance. The lack of pronounced OA blood glucose-lowering effects observed may 
be attributed to experimental design and data presentation. The blood glucose 
concentrations were measured 24 h after the last dosing and by that time the administered 
OA or standard anti-diabetic drugs may have been metabolized. The peak hypoglycaemic 
effect of triterpene containing herbal extracts occurs 2-4 hours after administration, with 
blood sugar returning to pre-treatment levels in 6-10 hours (Kakuda, Sakane, Takihara, 
Ozaki, Takeuchi and Kuroyanagi, 1996). 
Plasma insulin concentrations were significantly elevated in non-diabetic rats 
administered insulin alone or in combination with OA by comparison with STZ-induced 
diabetic rats similarly treated. Therefore, insulin involvement in the hypoglycaemic 
effects of OA is excluded, since plasma insulin concentrations of non-diabetic and STZ-
induced diabetic rats were not altered by treatment with OA alone. OA, however, would 
not be expected to significantly affect insulin levels in STZ-induced diabetic rats as the 
pancreatic 6-cells would have been selectively destroyed by streptozotocin administration 
(Junod, Lambert, Stauffacher and Renold, 1969; Pinent et ah, 2004). It is possible that 
OA alters glucose metabolism in the liver of diabetic animals, thus reducing blood 
glucose concentrations by increasing hepatic glycogenesis (Table 5). This has been 
previously reported for other plant extracts (Gondwe et al., 2008). It is suggested that the 
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hypoglycaemic effects of OA mimic those of metformin as evidenced by the fact that 
both these treatments did not alter plasma insulin concentrations (Figure 10 and 16). 
Metformin improves insulin sensitivity in peripheral target tissues and suppresses hepatic 
glucose output to reduce blood glucose (Lee and Morley, 1998; Krentz and Bailey, 2005). 
The possibility of lowering blood glucose concentrations through other mechanisms 
cannot be totally excluded. 
Hypoglycaemic effects were most pronounced in STZ-induced diabetic rats treated with 
combined OA and insulin (Figures 8 and 9). Since the current data suggest that OA 
possesses metformin-like blood glucose lowering properties, it is possible that OA 
augmented the hypoglycaemic effects of insulin by increasing the sensitivity to insulin. 
This is in agreement with previously reported effects of other triterpenoids, ursolic acid 
and corosolic acid (Miura et al., 2004; Jung et ah, 2007). It is also possible that OA might 
have interfered with gastric emptying and glucose absorption, as been previously reported 
for metformin (Lee and Morley, 1998). Indeed some triterpenoids have been shown to 
lower blood glucose concentrations in a similar way (Matsuda, Li, Yamahara and 
Yoshikawa, 1998; Matsuda, Li, Mukarami, Yamahara and Yoshikawa, 1999; Katz, 
Newman and Lansky, 2007). The ability of OA to prevent hyperglycaemia indicates that 
OA may be useful in preventing some of the complications associated with diabetes 
mellitus. 
OA like metformin and insulin increased hepatic glycogen concentrations of non-diabetic 
and STZ-induced diabetic rats by comparison with respective controls (Table 4). Hepatic 
glycogen concentrations were, however, significantly lower in STZ-induced diabetic rats 
as compared to the non-diabetic rats. Glycogen is the primary storable form of glucose 
and diabetes mellitus is associated with reduced capacity to store glycogen 
(Chandramohan, Ignacimuthu and Pugalendi, 2008). This is in agreement with previous 
observations that the crude leaf extract of S. cordatum increases hepatic glycogen 
concentrations, thereby reducing blood glucose levels (Musabayane, Mahlalela, Shode 
and Ojewole, 2005). On the contrary, muscle glycogen concentration of STZ-induced 
diabetic rats was not altered by treatment with OA alone, presumably due to the lack of 
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insulin. The observed difference between non-diabetic and STZ-induced diabetic rats 
muscle glycogen concentration may be due to the fact that the conversion of glucose into 
glycogen in skeletal muscle is dependent on insulin (Saltiel and Kahn, 2001; Hsu, Liu, 
Kuo, Chen, Su and Cheng, 2003; Jensen, Jebens, Brennesvik, Ruzzin, Soos, Engebretsen, 
O'Rahilly and Whitehead, 2006). In contrast, hepatic glycogen concentrations are 
determined by the extracellular glucose concentrations and glycogenic enzyme activities 
(Tana, Tanb and Pushparaj, 2005). It is possible; therefore, that OA-induced hepatic 
glycogen synthesis in STZ-induced diabetic rats was due to increased activities of GLUT-
2 and glycogen synthase (Buschiazzo, Exton and Park, 1970; Libal-Weksler, Gotlibovitz, 
Stark and Madar, 2001; Tana, Tanb and Pushparaj, 2005). The activity of the GLUT-2 
transporters is non-insulin dependent. Glycogen synthesis also involves inhibition of 
glycogen phosphorylase, decreased glucose output, enhancement of GLUT-4 
translocation, insulin receptor autophosphorylation and inhibition of protein tyrosine 
phosphatase B as been reported for other triterpenoids (Chen et al., 2006; Jung et ah, 
2007). It is possible to speculate that the effects of the combined treatment could be due 
to OA sensitizing responses to exogenous insulin. 
The non-diabetic rats showed weight gain throughout the study, whilst untreated STZ-
induced diabetic rats showed progressive weight losses. The discrepancy between the 
groups may be attributed to the anabolic effects of insulin (Chandramohan, Ignacimuthu 
and Pugalendi, 2008). Treatment with OA alone or in combination with insulin, however, 
stabilized body weight of STZ-induced diabetic rats without altering food intake. Weight 
gain may be attributed to increase in the incorporation of glucose into tissues, as reported 
earlier in STZ-treated diabetic mice (Naik, Barbosa-Filho, Dhuley and Deshmukh, 1991; 
Okine, Nyarko, Osei-Kwabena, Oppong Barnes and Ofosuhene, 2005). Interestingly, 
polydipsia and increased water intake as a result of enhanced proteolysis associated with 
hyperosmotic dehydration has been shown to be associated with weight losses in STZ-
induced diabetic rats (Rebsomen, Pitel, Boubred, Buffat, Feuerstein, Raccah, Vague and 
Tsimaratos, 2006; Narendhirakannan, Subramanian and Kandaswamy, 2006). 
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4.4. Renal effects 
Renal function studies were designed to investigate whether S. cordatum derived OA can 
reverse the previously reported inability of the kidney to excrete Na+ in STZ-induced 
diabetic rats (Musabayane, Ndhlovu and Balment, 1995). The hypotonic saline used has 
been shown to suppress endogenous arginine vasopressin secretion in rats (Balment, 
Brimble, Forsling and Musabayane, 1984). Long-term diabetes mellitus complications 
often include compromised kidney function and elevated blood pressure (Haller, Drab 
and Luft, 1996; Stengel, Billon, van Dijk, Jager, Dekker, Simpson, Briggs, 2003). The 
results indicate that OA not only has the potential to lower blood pressure in diabetes, but 
may also have beneficial effects on kidney function. The results introduce the first in vivo 
evidence that oleanolic acid extracted from S. cordatum leaves ameliorates kidney 
function in STZ-induced diabetic rats. 
Kidney weights of STZ-induced diabetic rats were significantly increased by comparison 
with non-diabetic animals possibly due to accumulation of extra cellular matrix proteins 
(Aybar, Riera, Grau and Sanchez, 2001; Kang, Kim, Yamabe, Nagai and Yokozawa, 
2006). The extra-cellular matrix protein induced kidney hypertrophy causes structural 
changes of glomerular basement membrane thereby impairing kidney function (Hargrove, 
Dufresne, Whiteside, Muruve, Wong 2000; Mason and Wahab, 2003; Kumar, Shetty, 
Salimath. 2008). This perhaps explains why STZ-induced rats exhibited marked daily 
decreases in urinary Na+ excretion and elevated plasma creatinine concentration with 
concomitant reduction in Ccr at the end of 5 weeks by comparison with non-diabetics. 
These changes were attenuated in the OA-treated groups indicating that oleanolic acid 
might have beneficial effects on renal function in diabetes. OA-evoked increases urinary 
Na+ outputs of STZ-diabetic rats and elevation of GFR as assessed by creatinine 
clearance suggest up-regulation of renal function by the triterpene. GFR is an important 
marker of kidney function and treatment-related increases in creatinine clearance indicate 
an improvement of kidney function in experimental animals and man rather than looking 
at plasma concentrations of urea because the latter varies with dietary protein (Satirapoj, 
Supasyndh, Patumanond and Choovichian, 2006; Yang and Bankir, 2006; Almond, 
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Siddiqui, Robertson, Norrie and Isles, 2008; van Hoek, Lefebvre, Kooistra, Croubels, 
Binst, Peremans and Daminet, 2008). Our laboratory and several other authors have 
previously used creatinine clearance (Ccr) in rats as a fundamental parameter of 
evaluating renal tubular function (Rebsomen et ah, 2006; Kumar, Shetty and Salimath, 
2008). Low GFR is associated with fluid and electrolyte imbalance in nephrotic 
syndrome and acute renal failure (Fernandez-Llama, Andrews, Nielsen, Ecelbarger and 
Knepper, 1998; Kwon, Frokiaer, Fernandez-Llama, Knepper and Nielsen, 1999; Kim, 
Jeon, Lee, Kang, Kook, Ahn, Kim, Cho, Kim, Han and Choi, 2000). A correlation 
between increased urinary Na+ excretion and elevated GFR has been reported in the rat 
(Marin-Grez, Fleming and Steinhausen, 1986). It is speculated that the effects of OA on 
renal Na+ excretion can be dissociated from its influence on fluid handling. Indeed, some 
studies dissociate the arginine vasopressin evoked increase in Na+ excretion via Vi 
receptors (Musabayane, Forsling and Balment, 1997) from its V2 mediated antidiuretic 
effects. It is speculated that OA administration significantly increased urinary Na+ 
excretion perhaps in part mediated via elevation of GFR possibly due to increases of the 
filtered load of Na+ in the tubular filtrate. In addition, OA may have inhibited increased 
proximal reabsorption of Na+ which occurs in diabetes mellitus (Palm, Liss, Fasching, 
Hansell and Carlsson, 2001; Vallon, 2003; Rebsomen et ah, 2006; Kanetsuna, Hirano, 
Nagata, Gannon, Takahashi, Harris, Breyer and Takahashi, 2006). Hence, OA improved 
kidney function in diabetic rats despite the failure to reduce elevated plasma urea 
concentrations. Kidneys maintain optimum chemical composition of body fluids by 
removal of urea and creatinine and the concentrations of these metabolites increase in the 
blood during renal disease. The low plasma creatinine concentrations probably explain 
the observed increase of GFR of both non-diabetic and STZ-induced diabetic rats treated 
with OA (Table 4). The influence of kidney mass on GFR in non-diabetic and diabetic 
rats is unclear as evidenced in the current study. Indeed, there were no apparent 
differences in kidney mass in all animals though there were apparent differences in GFR 
between the control and OA-treated animals. It is, therefore, hypothesized that the 
differences observed in GFR between control and treated rats are probably due to OA 
treatment. 
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OA treatment had no effect on urine flow in non-diabetic and STZ-induced diabetic rats, 
though it reduced water intake by the STZ-induced diabetic rats. The mechanisms by 
which OA caused these effects could not be elicited in this study. The increased water 
intake by STZ-induced diabetic rats was perhaps due to polydipsia arising from polyuria. 
This hypothesis is supported by marked increases in plasma osmolality of STZ-induced 
diabetic rats compared with the non-diabetic rats. Treatment with OA reduced water 
intake and plasma osmolality of STZ-induced diabetic rats at the end of the 5-week period 
perhaps due to increased Na+ excretion and improved glycaemic control. Indeed OA 
decreased urine glucose outputs of STZ-induced diabetic rats, suggestive of improved 
glycaemic control (Rebsomen et al., 2006). The mechanisms involved in the reduction of 
urine glucose could not be elicited in this study. 
OA reduced MAP of non-diabetic and STZ-induced diabetic rats. The potent hypotensive 
properties of OA confirm previous observations in Dahl salt sensitive rats (Somova, 
Shode, Ramnanan and Nadar, 2003). The mechanisms of this effect were, however, not 
elucidated in this study. We speculate this effect may possibly be modulation of the 
parasympathetic nervous system. The results are significant considering that diabetes is 
characterized by hypertension, and risks of cardiovascular morbidity and mortality (Palm, 




The results described in this study demonstrate that the S. cordatum leaf extract oleanolic 
acid (OA) has blood glucose lowering effects comparable to standard anti-diabetic drugs. 
Furthermore, OA augmented the hypoglycaemic effects of insulin in STZ-induced 
diabetic rats. The results also show that OA-elicited blood glucose-lowering effects in 
STZ-induced diabetic rats are in part mediated via increased hepatic glycogen synthesis. 
OA may, therefore, be useful as adjuvant treatment to enhance insulin effects in diabetes 
mellitus management. The administration of OA improved renal function of STZ-induced 
diabetic rats as shown by increased urinary Na+ outputs, reduction of plasma creatinine 
with concomitant increase in GFR. OA evoked potent hypotensive effects in STZ-
induced diabetic rats. The results introduce the first in vivo evidence that OA ameliorates 
kidney function in STZ-induced diabetic rats. This suggests that in addition to 
ameliorating hyperglycaemia and kidney function, OA has the potential to manage 
hypertension, a cardiovascular complication that frequently occurs as a result of diabetes 
mellitus. The findings described in this thesis are of considerable importance because 
they contextualize the hypoglycaemic, renal and hypotensive effects of OA in the 
management of diabetes mellitus. 
5.1. Shortfalls of the study 
The present study had some limitations to elucidate some of the mechanisms of the 
biological effects of OA. For instance the study did not investigate the effects of OA on 
reactive oxygen species generation in tissues, glycosylated haemoglobin, lipidaemia and 
glycogenic enzymes. Moreover, the effects of OA on renally active hormones such as 
aldosterone and vasopressin should have been established so as to relate to renal function 
parameters. 
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5.2. Recommendations for future studies 
This study has established increased glycogen synthesis as one of the blood glucose-
lowering mechanism of OA. Future studies should, therefore, investigate the effects of 
OA on glucose transporters as well as the enzymes involved in the glycogenic pathway. 
To establish the renal function effects of OA, hormones related to sodium homeostasis 
should be measured, such as aldosterone and vasopressin. Previous studies have indicated 
increased proximal reabsorption of sodium occurring in diabetes mellitus, with 
implications for the Na+-glucose co-transporters, therefore effects of OA on sodium 
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ABSTRACT 
Previous studies front our laboratories indicate thai the ami-diabetic effects of Syzvxiiim 
tonlutum (Hoc-list.) [Myrtacreie] leaf extract in strepioxolocin-inditced diabolic rats may 
be attributed in part lo mixtures of triterpenes, oleanolie acid f}(.Miytiroxy-olca-l2-en-
28-oie, acid. OA) and ursolic acid (3f5 -hydro.\yl-urs-12-cn-28-oic acid, iJA). for the 
bioaetivc compounds to have potential in diabetes management. the\ should alleviate or 
prevent complications of diabetes mellitus: kidney function and cardiovascular 
disorders. This study was. therefore, designed to assess whether ,S'. conlulum leal' 
derived OA influenced renal function evaluated by die ability to increase urinary Na" 
outputs parameters and creatinine clearance (C'crJ of streptuauocin (Sr/.l-irtdueed 
diabetic rats. Extraction and fractionation of S. coriiuium powdered leaf ethyl acetate-
solubles (b'AS) yielded mixtures of O A/It A and methyl nmslinate'Vncthyl corosolatc. 
Rccrystallisation of OAT'A mixiure using ethanoi afforded OA whose structure was 
con firmed by NMR spectroscopy ('fl & "C), .Acute effects of OA on kidney function 
and mean arterial blood pressure (.MAP) were investigated in anesthetized rats 
challenged with hypotonic saline after a 3.5-h equilibration for 4h of 1 h control, 1.5 h 
treatment and 1.5 h recover)' periods. OA was added to lite isrfnsate during the treatment 
period. Chronic effects of OA were studied in individually-caged rats treated twice daily 
with OA (60 ni|>/ki'„ p,o,) for 5 weeks, By eotnpari.son with respective control animals 
administrations OA significantly increased Na" excretion rates of non-diabetic and SI'Z-
mduced diabetic rats without affecting urine flow. K' ami Cf rates. At the end of 5 weeks, 
OA treatment significantly (p<0.()5) increased Ccr in non-diabetic (2.88±0.i4 vs 
3,71+0.30 ml/niin) and STZ-diabefie rats (i.81± 0.32 vs 3.07-TU6 ml/min) with 
concomitant reduction ol" plasma creatinine concentration (n--6 in all groups). OA also 
caused significant decreases in MAP in non-diabetic and STX-uxhiced diabetic rats. 
These findings suggest that OA may have* beneficial effects on some processes 
associated with renal derangement of SfZ-induced diabetic rais. 
Keywords: Renal function: diabetes inellitus; Iriterpcnes; oleanolie 
acid; Syzygium cuniatum. 
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INTRODUCTION 
i'lams containing triterpene constituents, oleanotie acid (38-lndroxy-olea-l 2-cn-28-oic 
acid, OA) and ursolic acid (3fi -b.ycSroxyl-urs-12-eti-28~oic acid, UA) have several 
traditional uses in folk medicines in terms of nirti-intianimatory, hepatoproteciive. 
analgesic, cardiotonic, sedative and tonic effects. ""' We have also recently reported 
that Sysygiuni asrdaium (Hoehst.) [Myrtaeeae| leaf extract with constituent mixtures of 
OA and UA possesses blood glucose lowering properties in strepfo/otoein-imiueed 
diabetic rats- Hyperglycemia is a major risk factor for the development and 
progression end stage renal failure: thus preventing the progression of kidney 
damage based on specific, alterations associated with nephropathy represents a serious 
medical challenge '"''. Studies, however, indicate that there is no effective treatment lor 
diabetic nephropathy. Current biomedical evidence indicates that some crude plant 
products and plant derived triterpenes ameliorate- the deterioration of kidney function in 
experimental animals. ' ' " '' In the present study, we thus tested the hypothesis that X 
coniatiim derived triterpene OA improves renal fluid and electrolyte handling in 
experimental diabetic animals. The main objective of the present study was. therefore, to 
assess whether S. cordaum leaf derived OA inlluenced renal functional parameters such 
as urinary Na outputs and creatinine clearance as a measure oi'OFR in the rats, >l>"<,i 
Since glomerular filtration rate (GFR.i determines the degree of electrolyte retention. | ! ' ' 
intervention trials in diabetes mcllitus should adopt reversing a decline in Cf'R as an 
outcome measure. We investigated the effects of OA on rcna! function because it is the 
main triferpeite that has been isolated front many medicinal plants. ! '8! 
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MATERIALS AND METHODS 
lirttit material 
Sszygium coniutum (Hoehsl.) IVfyitaeeae] leaves were collected around Durban, South 
Africa, between January and June 2006. The plant was identified by Professor II. 
Baijriath, the former Chief 1 axonomisOCurator of the University of KwaZulu-Nalal's 
Department of Botany. A voucher specimen (collector number MH/05) of the plant was 
deposited in the University's Botany Discipline Herbarium. 
Extraction 
Milled air-dried leaves of S cordalum (1,65 kg) were sequentially extracted thrice at 
24ii intervals with 3 litres on each occasion of hexanc. dicliloromethane. ethyl acetate 
and methanol. The solvents were removed under reduced pressure to give corresponding 
residues of bexane-softtbles (HKS) (10. Ig). dicliloromethane-solubles (DCMS) (29,3g>. 
ethyl acetate-solubles (TAS) (27.3gj, and methanol- solubles (MHS) (145.?u), 
respectively. Ihe crude ethyl acetate extract was subjected to further purification since 
previous studies indicated that CAS contained bioaclive compounds. '''' 
Isolation of oleanolie acid (OA) 
A portion of LAS (2g) was subjected to open column chromatography on silica gel (70-
230 mesh, 3.5 K 45cm) using a step gradient of D-hexane-ethyl acetate 90:10 (250mL). 
80:20 (250inl). and 70:30 iSOOinl). l-'raclions (Ci5) of 20ml... each were collected and 
monitored by TIX (,Si(K n-hexane/ ethyl acetate 7:3; anisaldeiiydeiUSO.i spray 
reagent}. The semi-polar column fractions (fractions 28-60. -640 ml,} enriched in 
irilerpenes were combined and submitted for further silica gel chromatography. OA 
(lOOiiig) was obtained as white powder and its structure was determined by *H- and '"'('-
MVfR (ID and 2D) spectroscopy (Figures 1), 
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Animals 
Male SpraguedAnvk:) rats {25!} ?t)0 g body weight) maintained under laboratory 
conditions of temperature, humidity and 12 h HgblM2 h dark regime <il She Biomedical 
Resource i.hiil, University oi'KwaZulu-Natai. were used. The rats were exposed to both 
food iF.pol-diel 4700, Bpol, South Africa) and water ad libitum. All experiments were 
performed in accordance with tSie University of KwaZulu-Naia! Research Fifties 
Committee guidelines for experimental animals. 
Induction of experimental diabetes 
Diabetes meliiius was induced with 60 mg/'kg of streptozotoein (Sigma Aldrieh. St. 
I.ouis. Missouri. USA) which was administered onee by inlraperitoneal injection, 
dissolved in citrate buffer, pi! 6,3 us previously described.''' Vehicle (curate buffer) -
injected animals acted as controls. Animals that exhibited gliteosuna after 24 hours, 
tested by urine test strips (Rapiclmcd Diagnostics. Sandton. South Africa), were 
considered diabetic. Blood glucose concentration of 2.0 mmoll measured after one week 
was considered as a stable diabetic state before our experimental procedures. 
Experimental design 
The effects of short-(acutc) administration of OA on renal fluid and electrolyte handling 
were evaluated in anesthetized male Sprague-Dawley non-diabetic and S'i'/-induced 
diabetic rats while the long-term (sribehronie) effects of OA on renal parameters and 
blood glucose were assessed in conscious animals. 
Acute studies 
Non-diabetic and STX-iridueed diabetic rats divided into groups of untreated control arid 
treated rats (n-6 in each group) were anesthetized by intraperitoneal injection of inactin 
(5-ethyl-5~(l'-mcthydpropyh-2-lhiobarbiiui'ate, 0.11 gy'kg body weight (Sigma Aldrich, 
St. Louis. Missouri. USA) and placed on a thermally-controlled beating tabic (37+IT ). 
After tracheotomy, a catheter was inserted into the jugular vein for intravenous infusion 
of 0.077M NaCl at 9 rnl/li (Harvard syringe infusion Pump 22. Harvard .Apparatus, 
IfoUiston, Massachusetts, USA). An additional heparinized catheter was also inserted 
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into she left carotid artery for blood pressure measurement at 30 min intervals via a 
pressure transducer (Statham Ml.'['0380. Ad Instruments. Bella Vista NSW. Australia), 
compatible with I'owcrfab System M1..4I0/W (Bella Visui NSW. Australia), following 
a V: ;• h equilibration period, measurements were recorded over die 4h posi-equilibration 
period oi' 1 h control. 1 h JO min treatment and 1 h 30 min recovery periods. 
In control groups, eight consecutive urine collections were made into pre-weighed 
plastic vials at 30 min intervals over the subsequent 4 h for measurements of urine How, 
Nad K.' and CI' excretion rates. In those animals in which the effects of OA were 
studied. t")-\ was added to the ittftisate at TO ug.; h for 1.5 h (treatment periods, resulting 
in a total dose of 0.45 irt;,y kg, respectively (for a 300 g rat) betore the animals were 
returned to infusaic alone for she last 1.5 h (recovery period). Depth of anesthesia was 
monitored throughout the experiments, and additional i.v. bolus doses of irtactin !.().!)> 
g/kg body weight) were administered when necessary. 
Chronic studies 
Non-diabetic and ST/.-indueed diabetic male Sprague-Uawley rats divided into groups 
of untreated and treated were used. The rats were given both food thpol-dief 4700, F.pol, 
South Africa! and water mi libilum. Separate groups of non-diabetic and SI /.-induced 
diabetic rats were treated with OA (60 nie/'kg, p.o.j twice every third day at 09h00 and 
1 5h(HJ for 5 weeks by means of a bulbed steel tube. fiaoh rat was housed individually in 
Makrolon polycarbonate metabolic cages (Teeniplast. Labotee, South Africa) kepi at the 
Biomedical Resource Unit, University of KwaAilu-Nutai to allow quantitative 
measurements every thiol day at OOhOO for 5 weeks of urine volume and analysis of Na'. 
K and CI". Rats treated with deionized water (3 uiL'kg. p.o.) acted as umreated 
controls. 
Mean arterial blood pressure (MAP) was monitored every third consecutive day for 5 
weeks at t)9h00 using non-invasive tail cuff method with photoelectric sensors (IITC1 
Model 31 Computerized Blood Pressure Monitor, Idle Sciences. Woodland Hills, CAj 
in all groups of animals. At the end of the 5-week experimental period, the kidneys 
were removed weights determined. Blood was collected from all groups of animals by 
cardiac puncture 24h after the last treatment. Blood glucose was measured using 
0 
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Bayer's glucomcter Mile" (Flite (Pry) Ltd, Health Care Division, South Al'ricaV i'he 
plasma concentrations, creatinine and urea were determined rising reagents reaecm kit.-; 
from Reekman Coulter'. Ireland, inc., and measured rising Beckman Coulter (Synehron 
LX.20 Clinical Systems. USA), <il;R values were calculated through the creatinine 
clearance tC u ) using the standard formulae following measurements of urine arid 
plasma concentrations of creatinine. Osmolalities of the plasma and urine were measured 
on 50 al samples by Iree/.ing point depression using, an osmometer (Osmomat 030. 1, asec 
i ahoraiory and Scientific Company, Berlin. Germany). 
Data analysis 
All data are expressed as mean = standard error of the mean iS.h.M.y The renal 
excretion data are presented graphically showing timed collections over the acute and 
subehronie experimental periods. The total amounts of fluid voided and electrolytes 
excreted durintr. the lh sfhnin administration of (DA were calculated and compared to 
values in controls for the corresponding tune. Al the end of 5 weeks, renal function was 
evaluated with 24 h Cer, plasma electrolytes, and urea and creatinine concentrations, do 
determine the effects of OA. the data were treated and presented separately for the non-
diabetic and SI/.-diabetic rats. All statistical calculations were performed with 
Graph Pad InStat Software (version 4.00, UraphPad Software, Inc.. San Diego. 
California. USA). Comparison between groups was performed using one-way analysis 
of variance tANOVA), followed by Tukey-Knrmer multiple comparison test. A value of 
p<(l,05 was considered significant. 
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RESULTS 
Structural elucidation of compounds 
Olcaiiolic acid spectral data identified by 'll- and ''Y'-NtMR (1U and 2D) compared 
with literature data, ' I lie purity (about 99%) til' OA was elucidated on the basis of 
chemical and physicocitemicai evidence f i'able 1). 
Acute renal effects 
I he mean Na" excretion rates of anaesthetized non-diabetic and S IZ-iuduced diabetic rats 
significantly increased during the 1 Ob OA administration by comparison with respective 
control animals (Figure J). Urine How. K.' and CI" rates, however, varied little during OA 
treatment period as evidenced by the tact that mean total volume of. fluid voided and the 
amounts of K" or CI' excreted did not significantly differ from those of respective control 
animals ('fable 2). OA, however, significantly elevated urinary Na' in both non-diabetic 
and Si /-induced diabetic rats. 
Subchronic renal OA effects 
1'he. moan weekly urine volume was elevated in untreated conscious STZ-indueed diabetic 
rats throughout the 5-week although the urinary electrolyte concentrations were 
significantly reduced compared to non-diabetic control animals, Subchronic 
administrations of OA (60 mg/kg, p.o.. twice every third day) to non-diabetic .and S'l'Z-
indtteed diabetic rats caused significant increases in urinary Na* outputs by comparison 
with respective control animals at (he corresponding time periods. The weekly urine 
volume, urinary K and CI" were, however, not altered by OA administration. By the 
end of the 5Bl week experimental period, plasma Na1'. K'and Cf were similar in 
untreated and OA treated STZ-indueed diabetic rats {Table 3), Conversely, plasma 
creatinine and urea concentrations were elevated in ST /.-induced diabetic rats in 
comparison with non-diabetic fats. OA treatment, however, significantly reduced 
(p- 0.05) plasma creatinine concentration of S'i'Z-indueed diabetic rats with a concomitant 
elevation in (SIR (fable si. 
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Effects of OA on blood and urinary glucose concentrations 
OA treatment CMS m».'kg. p.o.I twice every third day significantly fp* 0.05) decreased 
blood glucose and urinary glucose output oi' STX-induced diabetic rats Ibicure 5 and 
tabic 3). By the end oi' the 5-week study period. OA administration significantly 
reduced (p-'O.Oli plasma osmolality in STZ-trcated diabetic rats with concomitant 
increase in urine osmolality. The increase in plasma osmolality of non-diabetic rats did 
not achieve statistical significance level (fable ,yi. Kidney mass which was significantly 
increased in S'fZ-imiueed diabetic rats by comparison with non-diabetic animals was 
not altered by subchronic OA treatment (Table 3). 
Effects of OA on blood pressure 
Acute infusion of hypotonic saline to control non-diabetic ami STZ-induced diabetic 
animals did not show any significant variations in the mean arterial blood pressure 
throughout the 4-h post-equilibration period (Fisrure 4), OA administration, however, 
elicited immediate reduction of blood pressure which persisted during the post treatment 
period. Subchronic. treatment of the rats with OA (60 trtgdcg daily for 5 weeks, p.o.) also 
caused significant decreases in MAP in non-diabetic and STZ-treated diabetic rats 
throughout the study period by comparison with control rats at the corresponding period 
(Figure 4), 
DISCUSSION 
The experimental evidence presented in this study extends otir previous observations 
that S.cordatum leaf extract lowers blood glucose of STZ-tndnced diabetic rats, b'i jfe 
results indicate that the X ccruatiim leaf extracted trrterpene. oleanolie acid (OAt not 
only has the potential to lower blood pressure in diabetes, but may also have beneficial 
effects on the kidney function. Long-term diabetes mellitus complications often include 
compromised kidney function ' " ; and elevated blood pressure '*'. l'hc spectra of 
S.cordalum leaf extracted OA elucidated using 'id- and "C-NMR compared with 
previously reported data of oleanolie acid.;"'! 
In this study. SI /-induced rats exhibited marked weekly decreases in urinary Na' 
excretion and elevated plasma creatinine concentration with concomitant reduction in 
o 
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Ccr at the end of 5 weeks. These changes were attenuated in (he OA-ireated "roups 
indicalini: that oleanolic acid might have beneficial effects on renal function in diabetes. 
The OA-evoked increases urinary Na' outputs of S fZ-diabctic rats and elevated GFR as 
assessed h> creatinine clearanee suggest up-regulation of renal function by the 
triterpene We and several other authors have previously used Ccr in rats as a 
fundamental parameter of evaluating renal tubular function to monitor GFR. l v r ' '"''""' 
Low GFR is; associated with fluid and electrolyte imbalance in nephrotic syndrome ^ " 
and acute renal failure.i"'>"'"i It is, therefore, speculated that OA administration 
si an its cattily improved renal function of SI/"-induced diabetic rats perhaps in part 
mediated via elevation of GFR. We suggest that elevated GTR possibly increased the 
filtered load of Na" in the tubular iilirate thereby facilitating urinary Na* excretion. A 
correlation between increased urinary Na* excretion arid elevated GFR has been 
reported its the rat. ' ' ' ' The increased Na' excretion perhaps accounted for decreased 
plasma osmolality and increased 24-b urine osmolality at the end of the 5-vveck period. 
The beneficial effects of OA on kidney function in the ST7.-induced diabetic cannot be 
explained on gtycaeniic control us OA-treatmenl was unable ro achieve an etuiiyeaemic 
state and yet decreased urinary glucose output. 
We suggest that the triterpene ameliorates kidney function in diabetes as marked 
increased in creatinine clearanee despite the failure of OA to reduce elevated plasma 
urea concentrations of ST/.-induccJ diabetic rats. Treatment-related increases in 
creatinine clearance indicate improvement of kidney function in experimental animals 
''"''' and man !'~' rather urea because the latter varies with dietary protein. f""~'d Plasma 
creatinine concentration can, therefore, be used as a clinical chemistry end point to 
detect OA treatment-related effects on the kidney. Kidneys maintain optimum chemical 
composition of body fluids by removal of urea and creatinine and the concentrations of 
those metabolites increase in the blood during renal disease. 
Kidney weights of SI /'-induced diabetic rats were significantly increased by comparison 
with non-diahehc animals. Kidney hypertrophy due to accumulation of extra cellular 
matrix proteins is directly related to a decline in kidney function perhaps due to 
structural changes of glomerular basement membrane. '*"""'*' Typically, elevation of GFR 
accompanies increased kidney size as a result of increased glomerular volume and 
capillary surlacc area"'''. We hypothesize that the differences observed in GFR between 
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control and treated rats are probably due to OA tieatmem. This is supported bv the 
observation that kidney weights of treated non-diabetic and Si'/-induced diabetic rats did 
not differ from (host- of respective control animals. 
The potent hypotensive properties and amelioration of kidney function by OA of STZ-
•nduted diabetic rats confirms previous observations in Dalil salt sensitive rats. |!"! [n 
conclusion, tlie results of the present study introduce the first in vivo evidence that 
oleanolic acid extracted from ,S'. corjatiwi leaves ameliorates kidney function in STZ-
indttced diabetic rais. The possible mechanisms behind the OA-evoked amelioration of 
kidney function are yet to be studied. The results are significant considering that; 
impaired kidney function in diabetes is characterized by a progressive decline in (jFR. 
hypertension, and a high risk of cardiovascular morbidity and mortality. 
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Figure 2. KMR spectra 'll- (A). ''(?- (B), Distortion Enhancement Proton 








Figure 3. Comparison of the- effects of OA treatment on Na" excretion rates non-
diabetic (A-B) and ST/.-indueed diabetic rats (C-I)) with respective control animals. 
Values arc presented as means and vertical bars indicate SI- of means (ivf> in each 
group). 
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Figure 4, Comparison of the effects of OA treatment on mean arterial blood pressure 
(MAP) of non-diabetic (A-B) and SfZ-indueed diabetic rais (C-O) with the respective 
control, animals. Values are presented as means and vertical bars indicate SI: of means 
(n~(> in each group). 
* p'• 11.1)5 by comparison with respective control animals 
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Figure 5. Comparison of mean weekly urinary glucose outputs of control SI/.-induced 
diabetic rats and S I'/.-induced diiibetit rats treated wish OA (60 mg/kg, p.a.) twite every 
third day at WliOO and 1 ShOO lor 5 weeks. 
* p<tU)5 by comparison with control animals 
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Table I. "CUOO.fvl VlH/i Bruker Avance HI NMK spectral data of plant derived OA 
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Table 2. Total amounts of urine voided and NV. K", and (."!' excreted by non-diabetie 
and ST/.-diabetie control mud rats during lOh OA treatment period (n = 6 in all groups,]. 
Group Treatment Urine volume ; Ma" K* CI" | 
(mi) (jtimii) (fini(il) \ (funol) I 
Nun diabetic Control 13.1±1 I ll^i > _^ O ' " ; 12M±t4 ! 
" I V.i-1 n-;"*" Tu~\l [~13K8--i43 | 
_ _ ^ _ 2Mh^i, I ' j Q j ^ J ^ r - ] 







in 4 0 
OA It). 0 1 
*p<0.05 by comparison with respeelive control animals 
p*'0.05 by comparison with non-diabetie animals 
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Tabic ?, Effects of OA on solute excretion ami plasma biochemical parameters in non-
diaheiie and STZ-diabctic control and rats administered OA twice every third 
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*P'0.05 by comparison with respective control animals 
' p'0.05 by comparison with non-diabetic animals 
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APPENDIX IV (a) 
19. -COMPETITION 
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APPENDIX IV (b) 
-; V . RD/04/08 
ANT-DERIVED OLEANOLIC ACID IN SPRAGUE DAWLEY RATS 
'Tuf ts , MA, ^Oyedeji, OO, +Shode FO & *Musabayane, CT 
rysiology and *Chemistry, University of KwaZulu-Natal, Westville Campus, 
an 4000, South Africa. 
the ethanolic crude Syzygium cordatum (Hochst.) [Myrtaceae] leaf extract 
etes mellitus management, perhaps due to triterpenoid constituents. 
.ontrol of diabetes mellitus should include prevention or alleviation of renal 
tes is associated with impaired kidney function. 
was to investigate the renal effects of S. cordatum leaf-derived oleanolic 
ats. 
6kg) (milled) of S. cordatum was sequentially extracted with hexane, 
Detate, and methanol to give hexane —solubles (HS), dichloromethane-
tate-solubles (EAS), and methanol-solubles (MS). Preliminary experiments 
ned bioactive compounds. A portion of the EAS was subjected to column 
:a'gel. Gradient elution with n-hexane-ethyl acetate (9:1 to 6:4) produced 
re combined on the basis of their TLC similarities into three major sub-
i-polar fraction (F1) was discarded and semi polar/polar fractions (F2 and 
1 to silica gel column chromatography. F2 gave a mixture of oleanolic acid 
>. F3 gave a mixture of methyl maslinate and methyl corosolate. 
)A/UA mixture afforded OA (mp > 300°C [Lit. 306-308°C] using ethanol 
rture was confirmed by NMR spectroscopy (1H & 13C) (Seo ef a/., 1975). 
rlriey function and mean arterial blood pressure (MAP) were investigated in 
iged with hypotonic saline after a 3.5-h equilibration for 4h of 1 h control, 1.5 
:pvery periods. OA was added to the infusate during the treatment period." 
Liced significant (p<0.01) decrease in Na+, K+ and C!" excretion rates without 
Furthermore, OA significantly (p<0.05) reduced the MAP from a mean pre-
rnmHg to reach 105±1 mmHg after the cessation of treatment. The blood 
ased by the end of the 4-h experimental period to values that did not 
tt of control animals at the corresponding period. 
jat.OA at the dose used may influence kidney function. Further studies are 
DA leads to impairment of renal electrolyte excretion. 
vnimal 
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APPENDIX IV (c) 
Dear author, 
Thank you for submitting your abstract entitled "RENAL EFFECTS OF PLANT-DERIVED 
OLEANOLIC ACID IN STREPTOZOTOCIN-INDUCED DIABETIC RATS". Your reference number 
for this submission is 0009 A copy of your submission is attached to this email. 
The abstracts will be reviewed shortly and you will be informed by January 2009 whether or not your 
abstract has been accepted for presentation. Please remember to quote the conference name and the 
reference number in any communication with us. 
With best wishes, 
Conference Administrator 
Society for Endocrinology BES, HARROGATE 2009 
THE EFFECTS OF COMBINED PLANT DERIVED OLEANOLIC ACID AND 
INSULIN ON BLOOD GLUCOSE CONCENTRATION IN STREPTOZOTOCIN-
INDUCED DIABETIC RATS 
* Cephas T Musabayane. *Rudo F Mapanga, *Mark A Tufts, # 0 0 Oyedeji, & #Francis O. 
Shode 
^Disciplines of Human Physiology and Chemistry, University of KwaZulu-Natal, Westville 
Campus, Private Bag X54001, Durban 4000, South Africa. 
We have previously attributed the hypoglycaemic effects of Syzygium cordatum leaf extract to 
crude ethyl acetate extract solubles (EAS) containing triterpenoid compounds. The present study 
was designed to isolate and characterize triterpene components EAS and investigate the 
antihyperglycaemic effects alone or in combination with insulin in non-diabetic and 
streptozotocin (STZ)-induced diabetic rats. EAS soluble extracts were obtained after defatting 
the S. cordatum leaves with hexane followed by dichloromethane before maceration with ethyl 
acetate. Column chromatography on silica gel using n-hexane-ethyl acetate yielded mixtures of 
oleanolic acid, ursolic acid, methyl maslinate and methyl corosolate. Oleonolic acid (OA) was 
obtained by recrystallisation and its structure was determined by !H- and 13C-NMR 
spectroscopy. Oral glucose tolerance test (OGTT) responses were monitored in separate groups 
of non-diabetic and STZ-induced diabetic rats given glucose load after 18-h fast, followed by 
various OA doses (40, 80 and 120 mg/kg, p.o.). Rats treated with deionized water (3 ml/kg, 
p.o.), or insulin (200 \xg/ kg, s.c) acted as untreated and treated positive controls, respectively. 
The influence of OA on insulin-induced OGTT responses were studied in separate groups of 
animals that were treated with combined OA (40 or 80 mg/kg) and insulin (100 or 200 ng/kg, 
s.c). Blood glucose was monitored at 15-min intervals for the first hour, and hourly thereafter 
for 3h. All doses of OA as well as insulin significantly (p<0.05) decreased blood glucose 
concentrations of non-diabetic and STZ-induced diabetic rats. More notable, however, were the 
dramatic hypoglycaemic effects produced by combined OA and insulin administration. 
Compared with rats separately administered with insulin or OA, blood glucose concentrations 
were significantly (p<0.05) lower at all the time points that blood was sampled in animals 
treated with combined OA and insulin. We suggest that OA may be useful as adjuvant treatment 
to enhance insulin effects in diabetes mellitus management. 
Key words: Diabetes mellitus; hypoglycaemic plants; Syzygium cordatum, triterpernoids; 
oleanolic acid. 
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APPENDIX IV (d) 
Dear author, 
Thank you for submitting your abstract entitled "RENAL EFFECTS OF PLANT-DERIVED 
OLEANOLIC ACID IN STREPTOZOTOCIN-INDUCED DIABETIC RATS". Your reference number 
for this submission is 0050. A copy of your submission is attached to this email. 
The abstracts will be reviewed shortly and you will be informed by January 2009 whether or not your 
abstract has been accepted for presentation. Please remember to quote the conference name and the 
reference number in any communication with us. 
With best wishes, 
Conference Administrator 
Society for Endocrinology BES, HARROGATE 2009 
RENAL EFFECTS OF PLANT-DERIVED OLEANOLIC ACID IN 
STREPTOZOTOCIN-INDUCED DIABETIC RATS 
*Rudo F Mapanga,*Cephas T Musabayane, *Mark A Tufts, # 0 0 Oyedeji, & #Francis O. 
Shode 
*Disciplines of Human Physiology and Chemistry, University of KwaZulu-Natal, Westville 
Campus, Private Bag X54001, Durban 4000, South Africa. 
We have previously attributed the hypoglycaemic effects of Syzygium cordatum leaf extract to 
crude ethyl acetate extract solubles (EAS) containing triterpenoid compounds. The present study 
was designed to isolate and characterize triterpene components EAS and investigate the 
antihyperglycaemic effects alone or in combination with insulin in non-diabetic and 
streptozotocin (STZ)-induced diabetic rats. EAS soluble extracts were obtained after defatting 
the S. cordatum leaves with hexane followed by dichloromethane before maceration with ethyl 
acetate. Column chromatography on silica gel using n-hexane-ethyl acetate yielded mixtures of 
oleanolic acid, ursolic acid, methyl maslinate and methyl corosolate. Oleonolic acid (OA) was 
obtained by recrystallisation and its structure was determined by 'H- and 1JC-NMR 
spectroscopy. Oral glucose tolerance test (OGTT) responses were monitored in separate groups 
of non-diabetic and STZ-induced diabetic rats given glucose load after 18-h fast, followed by 
various OA doses (40, 80 and 120 mg/kg, p.o.). Rats treated with deionized water (3 ml/kg, 
p.o.), or insulin (200 ug/ kg, s.c) acted as untreated and treated positive controls, respectively. 
The influence of OA on insulin-induced OGTT responses were studied in separate groups of 
animals that were treated with combined OA (40 or 80 mg/kg) and insulin (100 or 200 ng/kg, 
s.c). Blood glucose was monitored at 15-min intervals for the first hour, and hourly thereafter 
for 3h. All doses of OA as well as insulin significantly (p<0.05) decreased blood glucose 
concentrations of non-diabetic and STZ-induced diabetic rats. More notable, however, were the 
dramatic hypoglycaemic effects produced by combined OA and insulin administration. 
Compared with rats separately administered with insulin or OA, blood glucose concentrations 
were significantly (p<0.05) lower at all the time points that blood was sampled in animals 
treated with combined OA and insulin. We suggest that OA may be useful as adjuvant treatment 
to enhance insulin effects in diabetes mellitus management. 
Key words: Diabetes mellitus; hypoglycaemic plants; Syzygium cordatum, triterpernoids; 
oleanolic acid. 
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